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This study focused on the effects of 
grain products and fish on metabolic 
profile. Metabolomics and lipidomics 
are modern technologies that allow 
characterization of the effects of diet 
in a much broader context than more 
conventional approaches in nutrition 
research and could therefore help 
elucidate the complex relationship 
between nutrition and metabolism. 
This thesis indicated that even rela-
tively small changes in diet altered 
metabolic profiles, especially lipids 
related to peroxidation, inflamma-
tion and insulin signaling.
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ABSTRACT
Metabolic syndrome (MetS) increases markedly the risk for type 2 diabetes mellitus
(T2DM), but in contrast to advanced T2DM, MetS and pre-stages of T2DM may be
reversible conditions, if addressed early enough by lifestyle modifications. Based on
epidemiological evidence, whole grain foods, fatty fish and polyphenol rich fruits and
vegetables, including berries, may help prevent the development of T2DM and
cardiovascular diseases (CVD), but evidence from clinical trials is not incontestable.
Metabolomics and lipidomics allow characterization of the effects of diet in more detail than
more conventional approaches in nutrition research and could therefore help elucidate the
complex relationship between nutrition and metabolism.
The overall aim of this work was to study the effects of whole grain, low insulin response
grain products and rye, fish, and bilberries in subjects at increased risk for MetS or CVD by
applying metabolomics approaches, with specific emphasis on the characterization of
molecular lipids by lipidomic approaches.
The intake of whole grain or rye over a period of 12 weeks did not change lipidomic
profiles. In contrast, a diet rich in oat-wheat bread and potato in the same study increased
proinflammatory lysophosphatidylcholines. Consumption of high-fiber rye bread over a
period of 8 weeks increased specific plasma metabolites that might mediate positive effects
of rye bread on satiety and weight maintenance. In another study, the consumption of fatty
fish decreased ceramides and diacylglycerols which are potential mediators of lipid induced
insulin resistance and inflammation. In a 12-week intervention study, diet rich in whole
grain and low insulin response grain products, fatty fish and bilberries altered lipidomic
profile especially increasing triacylglycerols with long chain (n-3) polyunsaturated fatty
acids. Increases in eicosapentaenoic acid and docosahexaenoic acid were associated with
improved insulin secretion and glucose disposal.
In conclusion, this thesis indicated that metabolomics is a valuable tool for studying effects
of dietary interventions at the molecular level. Dietary changes altered metabolic profiles,
e.g. altering lipids related to peroxidation, inflammation and insulin signaling, which may
further affect predisposition to T2DM and CVD in high-risk persons.
National Library of Medicine Classification: QT 235, QU 85, QU 120, WB 431, WG 120, WK 820
Medical Subject Headings: Metabolomics; Diet; Lipids; Cereals; Fishes; Fatty acids; Metabolic
syndrome X
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TIIVISTELMÄ
Metabolinen oireyhtymä on riskitekijäkasauma, jonka tunnusomaisia piirteitä ovat mm.
ylipaino ja insuliiniresistenssi. Se lisää merkittävästi 2-tyypin diabeteksen ja sydän- ja
verisuonitautien riskiä, mutta on hyvin hoidettavissa elämäntavoilla. Täysjyvävilja,
rasvainen kala ja runsaasti polyfenoleja sisältävät kasvikset ja hedelmät, mukaan lukien
marjat, voivat auttaa mainittujen sairauksien ehkäisyssä, mutta tätä ei ole osoitettu
yksiselitteisesti interventiotutkimuksissa.
Metabolomiikka on uudehko menetelmä, jolla voidaan tutkia kokonaisvaltaisesti
pienimolekyylisten aineenvaihduntatuotteiden rakennetta ja toimintaa. Metabolomiikan
alalaji lipidomiikka, johon tässä väitöskirjatyössä erityisesti keskityttiin, mahdollistaa yli
300 rasvamolekyylin tarkastelun, ja se antaa yksityiskohtaista tietoa elimistön rasva-
aineenvaihdunnasta.
Väitöskirjatyössä selvitettiin täysjyväviljan, rukiin, kalan ja mustikoiden käytön vaikutuksia
metaboliseen profiiliin henkilöillä, joilla on suurentunut riski 2-tyypin diabetekselle sekä
sydän- ja verisuonitaudeille. Väitöskirjatyö osoitti, että metabolomiikka soveltuu hyvin
ravitsemustieteelliseen tutkimukseen ja antaa arvokasta lisätietoa perinteisten kliinisessä
käytössä olevien mittausten lisäksi. Tutkimuksissa havaittiin, että korkean insuliinivasteen
aiheuttavat viljatuotteet, kuten vehnä ja peruna, lisäävät tulehdukseen liittyviä
lysofosfatidylkoliinilipidejä seerumissa, kun taas runsas rasvaisen kalan käyttö vähentää
useita tulehdukseen ja insuliiniresistenssiin liittyviä lipidejä. Runsaskuituisen ruisleivän
nauttiminen liitettiin puolestaan mahdollisesti kylläisyyttä parantaviin
aineenvaihduntatuotteisiin. Täysjyväviljan, rasvaisen kalan ja mustikoiden nauttiminen
yhdessä ja niiden aiheuttamat muutokset plasman lipidiprofiilissa olivat yhteydessä
parantuneeseen glukoosi- ja insuliinimetaboliaan.
Yhteenvetona voidaan todeta, että ruokavalion viljatuotteet ja kala vaikuttivat metaboliseen
profiiliin mm. muuttaen hapettumiseen, tulehdukseen ja insuliiniresistenssiin liittyvien
lipidien pitoisuuksia, mikä puolestaan voi vaikuttaa 2-tyypin diabeteksen sekä sydän- ja
verisuotautien riskiin.
Yleinen suomalainen asiasanasto: ravinto; terveysvaikutukset; lipidit; viljavalmisteet; kala;
metabolinen oireyhtymä
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1 Introduction
The prevalence of metabolic syndrome (MetS), a cluster of major cardiovascular risk
factors related to overweight and insulin resistance, is increasing all over the world.
MetS increases the risk for type 2 diabetes mellitus (T2DM) markedly, but in
contrast to advanced T2DM, MetS and pre-stages of T2DM may be reversible
conditions, if addressed early enough by lifestyle modification. Nutrition, physical
activity  and  weight  loss  are  the  key  elements  in  delaying  or  preventing  the
development of T2DM.
The relationship between nutrition and metabolism is complex, and the exact
mechanisms  how  different  diets  affect  the  human  body  are  still  only  partly
understood. Metabolomics and other nutrigenomics approaches allow
characterization of the effects of a nutrient, a food or a diet with much more
precision than classical approaches in nutrition research. They help elucidate the
complex relationship between nutrition and metabolism, and the role which dietary
components play in health maintenance and the development of the diseases.
Lipids have many roles in the human body. Besides being an important energy
store, they act as structural and signaling molecules controlling important cellular
processes. Imbalances of important lipid signaling pathways contribute to disease
progression, for example in chronic inflammation, atherosclerosis, MetS and T2DM.
Lipidomics is a lipid-targeted metabolomics approach aiming at comprehensive
analysis of lipids in biological systems.
Based  on  epidemiological  evidence,  whole  grain  foods,  fatty  fish  and  polyphenol-
rich fruits and vegetables, including berries, may have health-promoting effects,
including prevention of T2DM and cardiovascular diseases (CVD). However, the
evidence from clinical trials is not incontestable, and underlying mechanisms are
poorly understood.  Rye bread, fish and bilberries have traditionally been part of the
Finnish cuisine, but lately they have been partly replaced by more energy-dense
nutrient-poor foods.
The aim of this work was to study the effects of whole grain, low insulin response
grain products and rye, fish, and bilberries in subjects at increased risk for MetS or
CVD by applying metabolomics approaches. The changes in the lipidomic profiles
were a particular focus. Furthermore, the effects of the above-mentioned diets were
studied at the level of adipose tissue gene expression and glucose and insulin
metabolism in plasma.
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2.1 METABOLOMICS
2.1.1 Definition and historical perspective
Metabolites, which are small intermediate molecules and products of metabolism,
play a key biological role as regulators of systems homeostasis. Metabolomics is a
discipline dedicated to the global study of metabolites, their dynamics, composition,
interactions, and responses to intervention or changes in their environment, in cells,
tissues or biofluids (1-3). Modern metabolomics began to develop in the 1970s when
Linus Pauling and colleagues determined 250 substances in a sample of breath, and
of about 280 substances in sample of urine vapor, and suggested that quantitative
analysis of body fluids might permit differential diagnosis of many diseases in a
more effective way than was possible at the present time (4).
However, not until the advances in analytical technologies and powerful
information technology solutions for handling large volumes of analytical data in
the late 1990s and 21st century did the rise of metabolomics really take place. While
in 1999 three articles containing the keywords metabolomics or metabonomics were
published, the number increased to 147 articles in 2003 and 203 in 2004 (5). In April
2011 these keywords gave 2785 hits in the PubMed Central. Modern metabolomics
have roots in plant research (6) and toxicology (7), but later on it has been applied
also in disease diagnostics (8) and nutrition (1).
2.1.2 Analytical platforms
Metabolomics is closely related to the basic aims of traditional biochemistry, but
what makes it different, is that the aim is to study the metabolome globally in the
context of organism physiology, rather than specific metabolite interactions or
conversion (2). Metabolome represents the entity of the metabolites within
biological system (9). The total number of metabolites in the human body is not yet
known and estimates are ranging from 3000 to 100 000 (10). At the moment Human
Metabolome Database includes nearly 8000 metabolites (11). These components
belong to a wide variety of compound classes, such as lipids, organic acids, amino
acids, sugars, etc, and are very diverse in their physical and chemical properties and
occur in a wide concentration range (5). Thus, global metabolome cannot be
measured using a single measurement, but multiple analytical platforms are applied
in parallel to cover a broad range of metabolites, which typically include different
extraction methods for specific groups of metabolites (2). Most commonly applied
technologies are based on liquid chromatography-mass spectrometry (LC-MS), gas
chromatograph-mass spectrometry (GC-MS), capillary electrophoresis coupled to
mass spectrometry (CE-MS) and nuclear magnetic resonance (NMR) (1, 5).
The analytical strategies for metabolomics can be broadly divided into non-targeted
and targeted methods or metabolic profiling and metabolic fingerprinting (1, 5, 12).
The non-targeted approaches aim to cover the metabolome as broadly as possible
3while characterizing metabolite changes semi-quantitatively or differentially,
whereas the targeted methods aim to quantify, i.e., determine absolute
concentrations of selected metabolites (1, 12).  Metabolic profiling focuses on the
analysis of a group of metabolites either related to a specific metabolic pathway or a
class of compounds (5, 13). Metabolic profiling includes target analysis, meaning a
very limited number of metabolites such as biomarkers of disease, toxic exposure or
diet. Metabolic fingerprinting means global screening approach to classify samples
based on metabolite patterns or “fingerprints” that change in response to disease,
environmental or genetic alterations with the ultimate goal to identify
discriminating metabolites (5).
2.1.3 Metabolomic work flow
A typical metabolomic workflow for targeted and non-targeted analyses is
presented in Figure 1. The first step is a sample collection, which is primarily driven
by the experimental design. There are multiple issues which need to be considered
during  sampling  in  order  to  avoid  unwanted  sources  of  variation,  e.g.  time  of
sampling, freezing, storage, preservatives, materials of collection tubes, etc. (5, 14).
Sample preparation includes extraction of analytes from complex biological
matrices, such as plasma or urine, and bringing them into a format that is
compatible with the analytical technique used.  NMR-based approaches generally
require less sample pretreatment than MS-based approaches (15). In targeted
analyses, sample preparation can be tailored for the target metabolites, because the
analytes are known, and surrogate compounds, or stable isotope-labeled standards
can be used (5).  In contrast, in the non-targeted analyses, all small molecules are
targets and only salts and macromolecules can be considered as matrix.
Consequently, a sample preparation process should be as simple and universal as
possible.
Metabolomics analyses using MS detection are commonly applied in combination
with  a  separation  technique,  like  LC  or  GC,  which  reduces  the  complexity  of  the
mass spectra. Samples are introduced to the LC column, where the molecules
separate based on their size, affinity to stationary phase, polarity, or hydrophobicity.
The retention time measures the time which it takes to an analyte to pass from the
column inlet to the detector. In analyses of complex samples, it is likely that many
analytes elute at the same time, and individual compound peaks cannot be resolved
by LC alone. When coupled with MS, the coelutants enter the LC-MS interface,
where they are ionized and introduced into the mass spectrometer, where mass-to-
charge ratio (m/z) and intensity (ion count) are measured (2).
Technologies used in metabolomics produce large amounts of data, and its handling
tasks can be roughly divided in two steps: data processing and data analysis (16).
Typical data processing usually proceeds through filtering, peak detection,
alignment and normalization (2, 16). Filtering methods process the raw
measurement signal with aim of reducing complexity of spectra and removing
4noise.  The  purpose  of  peak  detection  is  to  identify  all  signals  caused  by  true  ions
and avoid detection of false positives. This step also aims to provide as accurate
quantitative information about ion concentrations as possible. Alignment match
corresponding peaks across multiple sample runs, and normalization removes
unwanted systematic variation in ion intensities between samples, while retaining
the interesting biological variation (16). The data analysis stage includes statistical
analysis of processed data (e.g. testing for differential expression, multivariate
analysis such as clustering), bioinformatics approaches (e.g. mapping to lipid
pathways) and interpretation (17, 18).
Figure 1. Typical simplified metabolomics workflow for targeted and non-targeted
analyses. (Modified from Oreši et al and Dettmer et al (1, 5).
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2.1.4 Metabolomics in health and nutrition research
Nutrigenomics tackles how diet influences gene transcription, protein expression
and metabolism (19, 20). Metabolomics and other omics approaches allow
characterization of the effects of a nutrient, a specific food, or a diet with much more
precision than classical approaches in nutrition research (14). They help elucidate
the complex relationship between nutrition and metabolism, and role that dietary
components play in health maintenance and disease development (20). By allowing
global profiling, untargeted approaches are efficient for hypothesis generation, and
the main importance lies in the possibilities of observing also phenomenon that
were not anticipated in advance (21). Metabolomics applications may also help solve
problems associated with the methods currently used for measuring food and
nutrient intake by discovering accurate biomarkers. For example, estimation of
dietary intake of the various phytochemicals ingested with our diet or dietary
supplements is difficult due to limited availability of food composition data for
phytochemicals and bias inherent in dietary assessment methods (22).
The human metabolic phenotype is very sensitive to internal and external stimuli,
which on the other hand enables detection of subtle effects of interventions, such as
change of diet, but on the other hand requires understanding of the sources and
extent of within- and between-person variation of metabolome depending on
different genetic and environmental factors (1, 10). For example, age, gender, diet,
gut microbiota, BMI and geography have been shown to alter the human
metabolome (23-25). To cope with inter-subject metabolic variation, one method is to
conduct  carefully  controlled  dietary  intervention  studies  with  a  cross-over  design,
where each subject participates both a control and intervention periods (20).
Consumption of a standard diet on the day before sample collection can reduce
between-person variation in the urinary metabolic profiles of healthy individuals,
but does not reduce variation in plasma or salivary metabolic profiles (26).
Identification of genetic and environmental factor affecting the metabolome can best
be achieved in the twin setting. It was demonstrated with 18-year-old healthy twins
that the individual genetic background contributes to the plasma metabolomics
profile (27). Another lipidomic study of monozygous twins discordant for obesity
showed that acquired obesity is characterized by the elevation of proinflammatory
lysophosphatidylcholines and diminishment of ether phospholipids that are known
to have antioxidant properties (28).
To bring metabolomics into practice, important challenges in knowledge and
technology need to be addressed (3). There are unsolved problems in every step of
metabolic workflow (Figure 1). One of the most notable is the difficulty in
identifying the metabolites influenced by a given nutritional intervention (14).
Another pressing problem is the difficulty in comparing data across different
experiments from different laboratories due to the lack of standardized methods
and inherent analytical challenges associated with application of nontargeted
methods (2, 14). There is also a large knowledge gap in the translation from
6metabolite concentration changes in body fluids to organ biochemistry and
physiological interpretation (14). Despite many analytical advances, no
metabolomics  method  can  cover  the  whole  metabolome,  so  any  analysis  is  only
giving a certain part of the picture.
2.1.4.1 Disease diagnostics
One of the fields where metabolomics has been applied is disease diagnostics (29).
Early diagnosis is of utmost importance in many diseases, since many complications
can be avoided or decreased by early intervention. Therefore metabolomics
strategies for identifying early biomarkers for diseases are very well-grounded.
T2DM  is  now  becoming  one  of  the  major  health  problems  in  developed  countries
and several studies have aimed to validate early biomarkers for it (30). For example,
Yuan and colleagues have shown metabolic differences between patients with
T2DM and healthy controls and identified five possible urinary organic acids as
potential biomarkers (31). Li and colleagues analyzed plasma from 48 diabetic
patients and 31 healthy controls and found five potential biomarkers for diabetes
including  glucose,  2-hydroxyisobutyric  acid,  linoleic  acid,  palmitic  acid  and
phosphate (32). Recently, Zhao and colleagues showed that investigation of either
plasma or spot urine led to clear separation of the clusters of subjects with impaired
glucose tolerance (IGT) and subjects with normal glucose tolerant (33).  Pre-diabetes
associated with alterations in fatty acid-, tryptophan-, uric acid-, bile acid-, and
lysophosphatidylcholine-metabolism. Subjects with IGT also showed decreased
level of gut flora-associated metabolites.
Possible disease biomarkers have been found also, e.g., for cancers (8), Parkinson’s
disease (34), celiac disease (35), and coronary heart disease (CHD) (36).  However, it
should  also  be  noted  that  the  discovery  of  a  potential  biomarker  is  only  the
beginning of the lengthy process of validating the biomarkers for the clinical setting
or for diagnostics (37).
7Figure 2. The development of disease from healthy (homeostasis with black dotted line)
to  sub-optimal  health  and  eventually  an  overt  disease  state.  Biomarker  patterns  (for
graphical reason represented as a single line) are essential to describe the changes from
normality to dysfunction. Nutritional metabolomics aim to help optimize nutrition for
health maintenance to restore homeostasis. Adapted from van der Greef et al (20, 38).
2.1.4.2 Nutritional biomarker discovery
There are few studies which have aimed to find biomarkers for the intake of
phytochemicals. GC-MS based profiling method was applied to urine and plasma
samples of 26 volunteers that participated in a placebo-controlled cross-over study
involving the consumption of a polyphenol-rich mixture of wine and grape juice
extracts (39). This study revealed 11 increased phenolic acids after polyphenol
treatment. NMR-based metabolomics approaches managed to characterize the
effects of black and green tea consumption on human metabolism (40), as well as
effects of a controlled intervention study comparing a 2 day-consumption of a low-
phytochemical diet and 2 day-consumption of the same diet supplemented with
fruit and vegetable drinks (41).
Stalmach and colleagues performed a feeding study in order to identify and
quantify compounds in the blood stream and excreted in urine by high performance
liquid chromatography coupled with MS (HPLC-MS) after the acute consumption of
coffee (42). The results showed that the urinary excretion of dihydrocaffeic acid-3-O-
sulfate and feruloylglycine may serve as very sensitive biomarkers for the
consumption of relatively small amounts of coffee. Coffee consumption may have a
role in human health, since coffee is the main source of strong antioxidant capacity-
possessing chlorogenic acids in the human diet.
8Few  studies  have  aimed  to  discriminate  between  meat  intake  levels  using
metabolomics, but at present there are no validated biomarkers of meat intakes (21).
In one of these studies, 12 healthy young males participating in a controlled cross-
over study consumed three diets for a 15-day period each, a high meat (150g/d), a
low meat (65 g/d) and a vegetarian diet offering same protein intake as high meat
diet. Urine samples were analyzed by NMR (43) . Urinary excretion of creatine,
carnitine, acetylcarnitine and trimethylamine-N-oxide increased in the high-meat
consumption period. In another study, 24 pre-pubertal boys were asked to consume
a daily supplement of skimmed milk or low-fat meat for seven days, each supplying
53 g protein (44). Urine and plasma samples were analyzed by NMR. This study
showed that urine metabolite profile was more susceptible to the effects of short-
term high intake of milk or meat protein than that of serum. The meat diet increased
urinary excretion of creatine, histidine and urea, while the milk diet reduced the
urinary excretion of hippurate.
2.1.4.3 Other applications
The INTERMAP metabonomics study aimed to develop metabolic phenotyping
approaches to elucidate aetiopathogenetic mechanism underlying the global blood
pressure problem and related disorders (25). Holmes and colleagues identified
urinary metabolites that discriminate across population defined by geographic or
dietary criteria and assessed independent relationships of these metabolites to blood
pressure. Urinary metabolic phenotyping identified alanine (direct) and hippurate
(inverse), reflecting diet and gut microbial activities, to be novel candidate
biomarkers that relate to blood pressure of individuals.
NMR based metabolomics was applied to investigate of human biological responses
to chamomile tea ingestion over a 6-week period incorporating a baseline, a
treatment, and a post-treatment period (45). Fourteen male and female subjects
participated in the study. In this experimental design, no food restrictions were
applied, but dietary information from the evening and morning preceding urine
collection was recorded. The depletion of creatinine and the elevation of hippurate,
glycine and an unidentified aromatic metabolite were strongly associated with
chamomile intake. In addition, the metabolic effects of chamomile ingestion were
prolonged in the 2-week post-dosing period. The observed metabolic alterations
were ascribed to possible chamomile-induced changes in gut microflora
metabolism. In multivariate analyses a metabolic confounding factor due to the diet
heterogeneity  within  the  trial  was  also  found.  The  confounding  factor  was  a  high
content of trimethylamine-N-oxide (TMAO), which is present in high levels in fish.
Inspection  of  the  diet  diaries  confirmed  the  link  between  fish  consumption  and
increased urinary excretion of TMAO.
Chorell and colleagues applied GC-MS based metabolomics in order to investigate
the complex metabolic responses caused by the interaction between physical
exercise and nutrition (46). Their objective was to study whether post-exercise
9ingestion of carbohydrates in combination with proteins generates a different
systemic human serum metabolic response, compared with the sole ingestion of
carbohydrates or water, in the early recovery phase following exercise.
Pseudouridine was suggested as a novel marker for the pro-anabolic effect
following low-carbohydrate-protein beverage ingestion. This conclusion was
supported by the decrease of the catabolic marker 3-methylhistidine and elevated
insulin concentration and increased availability of amino acids for protein synthesis.
The oral glucose tolerance test (OGTT) has been commonly used to determine how
glucose  is  cleared  from  the  blood  following  ingestion.  It  can  be  considered  a
standardized meal of pure liquid carbohydrates that evokes a variety of
physiological responses. Recent studies have reported detailed metabolic
characterizations of the glucose challenge. Shaham and colleagues studied healthy
and pre-diabetic patients and found that declines in glycerol, marker of lipolysis,
and leucine/isoleucine, markers of proteolysis, jointly provided the strongest
predictor of insulin sensitivity (47). Zhao and colleagues followed a variety of
physiological changes in the whole metabolic pattern in plasma during an OGTT in
healthy subjects. Using a nontargeted ultra performance liquid chromatography
coupled with MS (UPLC-MS), 11 500 metabolite ion masses per individual were
detected (48). Four groups of metabolites were detected as the most discriminating
OGTT biomarkers: free fatty acids (FFA), acylcarnitines, bile acids and
lysophosphatidylcholines (LPCs). These metabolites reflect a switch of the body’s
energy source from -oxidation of FFA released from the adipose tissue in the fasted
state toward glycolysis and fat storage.  Wopereis and colleagues showed that subtle
metabolic changes, resulting from pharmaceutical anti-inflammatory treatment of
overweight volunteers with elevated levels of the inflammatory plasma marker C-
creative protein, could only be determined using metabolic profiling in combination
with an OGTT (49).
2.2 LIPIDOMICS
2.2.1 Definition
Lipidomics is a lipid-targeted metabolomics approach aiming at comprehensive
analysis of lipids in biological systems (37). Recent advances in MS technologies and
improvements in chromatography have enhanced the developments and
applications of lipidomics. Traditional routine kit-based spectrophotometric
measurements for total and high-density lipoprotein (HDL) cholesterol and further
calculation of low-density cholesterol (LDL) levels by the Friedewald equation (50),
as well as determining serum total triacylglycerol (TG) levels are still reasonable and
informative methods to describe general lipid balance in the body (51). However,
the serum lipid profile is more complex and current lipidomics platforms enable
quantification of hundreds of diverse lipid molecules across multiple lipid classes
(52).
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2.2.2 Diversity of lipids
Lipids  consist  of  a  tremendous  number  of  structurally  and  functionally  distinct
molecular species that span from nonpolar (e.g. sterol esters) via neutral (e.g. TGs)
to polar (e.g. phospholipids) (37). Chemically lipids are defined as hydrophobic or
amphipathic small molecules that may originate entirely or in part by
carbanionbased condensation of thioesters (fatty acyls, glycerolipids (GLs),
glycerophospholipids (GPs), Sphingolipids (SPs), saccharolipids, and polyketides)
or by carbocation-based condensation of isoprene units (prenol lipids and sterol
lipids (ST)) (53, 54). Fatty acids (FA), as the simplest and one of the most important
lipid classes, are a basic element of all lipids. Functionally, fatty acids are precursors
of variety of bioactive lipid molecules (37). GLs, as another class of relatively simply
lipids, mainly include monoacylglycerides (MGs), diacylglycerides (DGs) (Figure 3
A)  and TGs (Figure  3  B).  These  lipid molecules  are  variable  in  the  number  of  FAs
that are esterified to the hydroxyl groups of the glycerol backbone.
As the major group of lipids, GPs cover mixtures of numerous molecular species
produced by glycerol with a functional polar head group attached to the sn-3
position via a phosphodiester bond with various combinations of different FAs at
the sn-1 and sn-2 position of the glycerol backbone (55). Based on the different polar
head  groups,  GPs  can  be  divided  for  example  into  glycerophosphocolines  (PCs)
(Figure 3 C), glycerophosphoethanolamines (PEs) and glycerophosphoserines (PSs).
GPs are  main components  of  cell  membranes  and participate  in  various  biological
activities involving cell signaling, membrane anchoring and substrate transport (37,
54,  56).  Also  STs,  consisting  of  cholesterols  and  derivates  with  a  four-ring  core
structure, are important components of membrane lipids and hormone precursors.
SPs are a complex family of compounds that share a common structure feature, a
sphingoid base backbone that is synthesized de novo from serine and long chain
fatty-acyl-CoA, then converted e.g. into ceramides (Figure 3 E),
phosphosphingolipids and glycosphingolipids (54).
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Figure 3. Examples of chemical structures of A) diacylglycerol, B) triacylglycerol, C)
phosphatidylcholine, D) lysophosphatidylcholine and E) ceramide.
2.2.3 Function of lipids
Fat  tissue is  the  most  abundant  energy store  in  the  body,  and it  consists  mostly  of
TGs.  Besides being an important energy store, lipids act as structural and signaling
molecules controlling important cellular processes, including cell proliferation,
apoptosis, metabolism and migration (55-57). While a significant portion of lipids is
synthesized via endogenous pathways, dietary lipids also play profound roles in
human health by influencing cellular functions, signaling, and energy utilization
(55). The fluidity of cell membranes is determined in part by the fatty acid
composition of the membrane phospholipids. The fluidity of membranes could be
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very important for receptor function and recycling and for the efficiency of signaling
pathways (58). Perturbations in important lipid signaling pathways contribute to
disease progression for example in chronic inflammation, autoimmunity, allergy,
cancer, atherosclerosis, hypertension, and metabolic and degenerative diseases (57,
59-62).
2.2.4 Lipids in metabolic syndrome and cardiovascular disease
2.2.4.1 Metabolic syndrome
MetS is a combination of medical disorders, including abnormalities in insulin,
glucose and lipid metabolism, hypertension and abdominal obesity, and it causes a
5-fold increase in risk for T2DM and more than doubles the risk for CVD over the
next 5 to 10 years (63-67). Over the past decade various diagnostics criteria for the
MetS have been proposed by different organizations, such as the National
Cholesterol Education Program Adult Treatment Panel III (68), the International
Diabetes Federation (69) and American Heart Association / National Heart, Lung
and Blood Institute (70). The main differences between these criteria concerned the
measure for central obesity. In 2009, several major organizations agreed on a
worldwide consensus definition of MetS, where three abnormal findings out of five
would qualify person for the MetS (Table 1) (66). A single set of cut points was
proposed for all components except waist circumference which would have national
or regional cut points until there is more reliable evidence of appropriate cut points.
Table 1. Criteria  for  clinical  diagnosis  of  the  metabolic  syndrome.  Three  out  of  five
criteria should be met (66).
Measure Cut points
Elevated waist circumference Population- and country-specific definitions 1
Elevated triglycerides  1.7 mmol/L 2
Reduced  HDL cholesterol < 1.0 mmol/L in males; <1.3 mmol/L in females 2
Elevated blood pressure 130/85 mm Hg 2
Elevated fasting glucose  5.6 mmol/L 2
1 e.g. for Europids:  94 cm in males and  80 cm in females, 2 alternatively drug treatment
The pathogenesis of MetS is heterogenous, but many lifestyle and genetic factors
clearly  interact  to  produce  it  (64,  71).  A  high  heritability  has  been  reported  for
fasting glucose and insulin, estimated insulin resistance, TGs and LDL and HDL
cholesterols in a healthy population (72) as well as pancreatic -cell function in
families with a high risk of T2DM (73). Association studies have been shown
multiple susceptibility alleles for MetS (74) in genes such as Fatty acid-binding
protein 2 (FABP2) (75), Beta-2-adrenergic receptor (ADRB2) (76), Interleukin 6 (IL-6)
(77) and Proliferator-activated receptor gamma (PPARG) (78). However, current
evidence suggests that even the relatively modest lifestyle changes including weight
loss, dietary changes towards current recommendations and increased physical
activity can greatly reduce the risk of diabetes in persons with impaired fasting
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glucose  or  glucose  tolerance  (79,  80).  These  findings  may also  be  applicable  to  the
prevention and treatment of the MetS.
2.2.4.2 Excess lipid accumulation
On an epidemiological level, as obesity increases, so does the prevalence of the MetS
and T2DM (81, 82). However, at the individual level, the association may not be so
clear cut (83). It also matters what kinds of and where excess lipids are stored, since
the deposition of excess lipids in non-adipose organs may cause lipotoxicity (83, 84).
This ectopic deposition of excess lipids in non-adipose organs, such as liver, muscle
and pancreatic beta-cells, is believed to create a process that causes adverse affects
on cellular metabolism, most notably insulin action.
One clinically manifest complication caused by deposition of excess lipids in liver is
nonalcoholic  fatty  liver  disease  (NAFLD)  (85,  86).  This  is  a  chronic  liver  condition
characterized by insulin resistance and hepatic fat accumulation (87).
Approximately 70% of persons with T2DM also have NAFLD (86). Saturated free
fatty acids may be especially harmful for liver since they cause endoplasmic
reticulum stress and apoptosis, as they are poorly incorporated into triglycerides
(88). Sources of hepatic lipids include dietary chylomicron remnants, free fatty acids
released from either adipose tissue TGs or chylomicrons hydrolyzed at a rate in
excess of what can be taken up by tissue and de novo lipogenesis (89). Notably,
lipidomics analyses revealed depletion of possibly beneficial long-chain
polyunsaturated fatty acids and increased DGs, which are immediate precursors of
TGs and associated with insulin resistance in the nonalcoholic fatty liver (90).
Similarly in muscle, the excess lipid accumulation may impair insulin action (91).
When fatty acids are taken up by muscle, they either undergo -oxidation in the
mitochondria, or they can be stored as TGs. Due to rate-limiting steps in -oxidation
and the limited storage capacity of muscle, the increased fatty acid flux seen in
obesity causes the accumulation in muscle of FA intermediates, including
lysophosphatidic acid (LPA), DGs and ceramides, which in turn can negatively
regulate insulin action (91-93).
2.2.4.3 Bioactive lipids in insulin resistance
Insulin resistance is a key feature of the MetS and T2DM (94). The hallmarks of
impaired insulin sensitivity in its target tissues are decreased insulin-stimulated
glucose uptake into skeletal muscle, impaired insulin-mediated inhibition of hepatic
glucose  production  in  liver,  and  a  reduced  ability  of  insulin  to  inhibit  lipolysis  in
adipose tissue (91). Two of the best-studied candidate lipid mediators that can
interfere with insulin signaling and glucose homeostasis are DGs and ceramides (94,
95).
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Ceramides
Ceramides consist of sphingoid base linked to a fatty acid via an amide bond
(Figure 3 E). Ceramide is the fundamental building block of other sphingolipids
including  sphingosine,  glucosylceramide  and  sphingomyelin  (SM)  (96).  Rates  of
ceramide synthesis depend largely on the availability of long-chain saturated FAs,
which participate in the initial, rate-limiting step in de novo ceramide synthesis (91,
97). In cultured myotubes, exposure to excess long-chain saturated FFAs (e.g.
palmitate, stearate and arachidate), but not unsaturated or shorter saturated FFAs,
was shown to promote ceramide formation (98, 99). The dependence of ceramide
synthesis on saturated fats makes it an attractive candidate linking lipid oversupply
to the antagonism of insulin signaling, as also dietary, epidemiological, and animal
studies suggest that saturated fats are more likely to contribute to insulin resistance
than their unsaturated counterparts (100-104). Some studies have also suggested
that cytokines such as IL-6 and tumor necrosis factor alpha (TNF-) might augment
de novo ceramide synthesis (100, 105, 106). Ceramides are also produced during the
catabolism of other complex sphingolipids, for example by the action of
sphingomyelinase (107, 108).
Ceramide concentrations are almost universally up-regulated in response to cellular
stress and they have an important role in growth arrest, oxidative stress, apoptosis
and necrosis (96). Recent data also suggest that ceramides may inhibit insulin action
in skeletal muscle, while its accumulation in the liver may not be sufficient to induce
insulin resistance (96). Inhibition of essential enzymes in the biosynthetic pathway
required  for  the  production  of  sphingolipids,  such  as  palmitoyltransferase  and
ceramide synthases, increases insulin sensitivity in animal models (109-112).
Moreover, plasma ceramide levels are elevated in obese T2DM subjects (113) and
several  groups  have  reported  elevations  in  muscle  ceramide  in  insulin  resistant
patients (114-116), though the finding is not universal (117). Furthermore, plasma
concentrations of ceramide were strongly positively associated with serum
circulating levels of IL-6 and insulin resistance in 33 patients with CHD (118).
Insulin promotes glucose uptake in skeletal muscle using a canonical signaling
pathway initiated by its tyrosine kinase receptor and culminating with the
translocation  of  the  glucose  transporter  type  4  (GLUT4)  to  the  plasma  membrane
(Figure 4) (96). The activated tyrosine kinase receptor phosphorylates a family of
insulin receptor substrates (IRS) that recruit and activate intracellular effector
enzymes (119). One of these proteins, lipid kinase phosphatidylinositol 3-kinase
(PI3K), is a requisite in insulin’s metabolic effects. PI3K initiates a widely conserved
signaling pathway leading to the activation of Akt2/protein kinase B- (Akt2/PKB-
), which is required for insulin –stimulated glucose uptake and anabolic
metabolism. Knockout mice lacking Akt2/PKB- become insulin resistant and
diabetic (120). Upregulating SP synthesis inhibits phosphorylation and activation of
all of the Akt/PKB isoforms without antagonizing upstream signaling events (121-
15
123). Only a few studies have evaluated ceramide action in adipocytes in vitro, but it
has been shown to inhibit insulin signaling and action also in adipocytes (96, 121).
Lipidomics studies have revealed that adipose tissue content of ceramides is
increased in subjects with increased liver fat compared with equally obese subjects
with normal liver fat content (124).
Figure 4. Simplified schematic depiction of the insulin signaling cascade and the possible
antagonistic effects of lipid metabolites. GLUT4, Glucose transporter type 4; IRS, insulin
receptor substrates; Jnk1, c-jun-N-terminal kinase 1; PI3, phosphatidylinositol 3-kinase;
PKB,  protein  kinase  B;  PKC,  protein  kinase  C;  PP2A,  protein  phosphatase  2A;  TNF-
tumor necrosis factor alpha.
Diacylglycerols
DG is a simple lipid consisting of a glycerol molecule linked through ester bonds to
two fatty acids in positions 1 and 2 (Figure 3 A) (125). Its small size and simple
composition enables it to act as a lipid intermediate in metabolism, as a component
of biological membranes and as a second messenger. DGs arise by several
mechanisms  e.g.  as  intermediates  both  in  the  biosynthesis  and  catabolism  of  TGs
and in the biosynthesis of certain phospholipids (107).
There  is  evidence  suggesting  that  increases  in  intracellular  DG  content,  due  to  an
imbalance between fatty acid delivery and intracellular fatty acid oxidation and
storage, may lead to activation of new protein kinase C (PKC) isoforms that in turn
via multi-phase signaling pathway inhibit insulin action in liver and skeletal muscle
(Figure 4) (95, 126, 127). Some studies have shown association between elevated DG
levels in skeletal muscle and insulin resistance in rats and humans (128, 129). In
contrast, Jocken et al recently reported that DG content was not elevated in skeletal
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muscle of obese-insulin resistant subjects and was even lower when compared with
lean men (130). Interestingly, fish oil has been shown to prevent fat-induced hepatic
insulin resistance and DG accumulation through a PPAR--dependent pathway in
mice (131).
2.2.4.4 Cardiovascular disease
The MetS is clearly associated with an increase in adverse cardiovascular outcomes,
but the relative risk varies depending on the definition criteria of MetS, study
population and adjustments for confounding factors (67, 132-135). A recent meta-
analysis showed a 2.35-fold increase in cardiovascular events in subjects with the
MetS  (67).  Patients  with  the  MetS  but  without  diabetes  still  had  a  high
cardiovascular risk. However, it is not clear whether the prognostic significance of
the MetS exceeds the risk associated with the sum of its individual components (134,
136, 137). The number of MetS components was shown to be linearly associated
with risk of CVD without an apparent threshold relationship (135). The relative risk
for CVD is higher in females with MetS or T2DM than in male counterparts (67, 135,
138).
T2DM is an independent risk factor for CVD (139-141). More than 70% of patients
with T2DM die of cardiovascular causes (142). The mechanisms linking pre-diabetes
and T2DM with CVD are not completely understood, but there are several potential
mechanisms, including oxidative stress, proteins glycosylation and enhanced
leukocyte-endothelial interaction, for high glucose to increase the risk of
atherothrombosis (143). Meta-analysis of 20 studies has demonstrated that already
in the nondiabetic range of glycemia (<6.1 mmol/l), increased glucose is associated
with an increased risk for CVD (144). However, pre-diabetic and diabetic subjects
often  have  a  clustering  of  different  CVD  risk  factors,  insulin  resistance,  obesity,
central obesity, elevate blood pressure, elevated total triglycerides and low HDL
cholesterol (142).
Dyslipidemias, including elevated serum total and LDL cholesterol and low HDL
cholesterol concentrations, are classical risk factors for CVD (145, 146). Diabetic
dyslipidemia, characterized by high triglycerides, low HDL cholesterol and
increased small dense LDL cholesterol concentrations, may be one factor
contributing to the increased risk of CVD in diabetic patients (147, 148). However,
the serum lipid profile is more complex, since the vascular plaques and lipoproteins
contain hundreds of lipid species that may exhibit various bioactive properties
affecting the course of CVD (61). For example, SPs play an important role in cell
membrane formation and plasma lipoprotein metabolism and may have an impact
on atherosclerotic development e.g. by increasing LDL cholesterol aggregation (149-
151). LPCs are also found in proinflammatory and proatherogenic conditions (152-
155).
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Lysophosphatidylcholine
LPC consists of one hydrophobic long fatty acyl chain and one large hydrophilic
polar choline headgroup, attached to the glycerol backbone. It is generated mainly
by phospholipase A2-induced hydrolysis of phosphatidylcholines (Figure 3 D) (156).
Appreciable amounts of lysophosphatidylcholine are formed by a specific enzyme
system, lecithin-cholesterol acyltransferase (LCAT), which catalyses the transfer of
fatty acids from position sn-2 of phosphatidylcholine to the hydroxyl group of free
cholesterol, resulting in the formation of cholesterol esters and LPC (107). Direct
hepatic secretion also is a quantitatively important source of plasma unsaturated
LPC (157).
Beside the function of membrane phospholipid metabolites, LPCs regulate a wide
variety of cellular activities, including proliferation, wound healing and smooth
muscle contraction (158). LPC is also a major phospholipid component of oxidized
LDL and has been implicated as a critical factor in the atherogenic activity of
oxidized LDL (159). LPCs are linked with atherosclerosis by multiple possible
mechanisms including upregulation of adhesive molecules (160), increase of
apoptosis (161) and release of arachidonic acid (162). They also induce increases in
several  inflammatory  cytokines  (IL-1,  IL-6  and  TNF-)  in  human  peripheral
mononuclear cells (163) and IL-1 in human monocytes (164). Saturated LPC(18:0)
produces more IL-1 than monounsaturated LPC(18:1). On the other hand, LPCs
have demonstrated also antiatherogenic effects (155, 165).
The  acyl  chains  in  LPC  and  LPA  molecules  vary  from  saturated  to  highly
unsaturated, and from 16 to 22 carbons. Their biological function may vary
depending on the acyl chain (155, 166, 167). Dietary EPA and DHA fatty acids are
incorporated into plasma LPCs (167), which may be important, since LPCs are
believed to be major carriers of DHA to the brain (168).
2.2.5 Lipidomics in health and nutrition studies
2.2.5.1 CVD and its risk factors
Lipidomics  technology  has  been  widely  applied  in  CVD  studies,  for  example  to
elucidate plaque biology, lipoprotein trafficking and metabolism and to aid in
diagnostics and treatment (61, 169).  The role of lipoproteins is to transport water-
insoluble lipids in biological fluids. Due to their importance in the development of
CVD, they have been extensively studied (169). A detailed article on lipid class and
species composition of lipoprotein fractions of healthy donors was recently
published by Wiesner and colleagues (170).  LDL fractions were enriched in
ceramides and SMs, whereas HDL contained 60% of plasma total content of PC, PE
and plasmalogens. Kotronen and colleagues performed lipidomic analyses of all
major  lipoprotein  fractions  in  16  individuals,  who  exhibited  a  broad  range  insulin
sensitivity (171). TG molecules containing saturated and monounsaturated fatty
acids correlated positively with features of insulin resistance within very low
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density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and LDL, but
not those within HDL. Fatty acid analyses revealed that saturated palmitic acid
(16:0) was positively related to HOMA-IR only when measured in VLDL, IDL and
LDL, whereas unsaturated linoleic acid (18:2n-6) was inversely related to HOMA-IR
in all lipoproteins. Lipotoxic ceramides were present within VLDL and LDL.
Furthermore, Yetukuri and colleagues studied HDL particles derived from subjects
with high and low HDL cholesterol. Low HDL subjects had elevated triacylglycerols
and diminished LPCs and SMs (172). The information on lipid molecular
composition  of  HDL  may  provide  better  insights  into  the  mechanisms  behind  the
anti-atherogenic role of HDL.
Graessler and colleagues showed by screening the plasma lipidome of 19 men with
hypertension and 51 normotensive male controls that hypertension was specifically
associated with diminished free cholesterol and ether lipids levels (173). Specifically,
ether phosphatidylcholines and ether phosphatidylethanolamies, which comprise
arachidonic and docosapentaenoic fatty acid moieties, decreased independently of
lipidomic alterations induced by obesity and insulin resistance. Obesity resulted in
generally higher lipid load in plasma, while the content of TGs and DGs increased
dramatically, whereas insulin resistance, controlled for BMI, had little effect on
plasma lipidome.
2.2.5.2 Glucose and insulin metabolism
A comprehensive lipidomics analysis was performed to provide molecular insights
into the relationship between insulin resistance and total serum TG levels (171).
Concentrations of 45 different TGs and fatty acid composition were determined in
serum from 16 individuals with a broad range of insulin sensitivity. TGs containing
saturated and monounsaturated FAs were positively correlated with HOMA-IR,
whereas TGs containing essential linoleic acid were negatively correlated. These
results suggest that serum concentrations of specific TGs, such as TG(16:0/16:0/18:1)
or TG(16:0/18:1/18:0) may be more precise markers of insulin resistance than total
serum TG concentrations.
Perturbations in lipid homeostasis have been linked to the type 1 diabetes (174, 175).
There are two recent studies in which lipidomics were applied to investigate
changes in the serum lipidome related to type 1 diabetes (176, 177). In the DIPP
(Type 1 Diabetes Prediction and Prevention) birth cohort study, Oreši and
colleagues compared serum sample series drawn from 50 children who during
follow up progressed to type 1 diabetes-associated autoimmunity and further to
diabetes and 67 controls who remained non-diabetic and autoantibody negative
(176). Individuals who developed diabetes had reduced serum levels of PCs at birth,
reduced  levels  of  TGs  and  antioxidant  ether  phospholipids  throughout  the  follow
up, and increased levels of proinflammatory LPCs several months before
seroconversion to autoantibody positive. These results suggest that metabolic or
immunomodulatory interventions during the preautoimmune period may be used
19
as a potential strategy for prevention of type 1 diabetes.  Sorensen and colleagues
characterized the lipid profile of 10 individuals with newly diagnosed type 1
diabetes and 10 non-diabetic controls, and found 559 lipid features which were
significantly differentiated between patients and controls (177). Most differentiated
lipids species belonged to PC-containing classes, such as LPCs, PCs and SMs.
2.2.5.3 Nutrition
The effect of diet-induced weight loss on plasma lipidomic profile was studied with
19 subjects (9 in the weight loss group and 10 in the control group) with features of
MetS in a 33-week intervention (178). Weight reduction of 7.8% resulted in
significant changes in the plasma lipidome compared with the control group even in
the absence of significant changes in classical lipid measures. TG and PC levels were
reduced, with no significant change in sphingolipid and LPC levels. The degree of
decrease of saturated and short-chain TG species was generally more pronounced
than for longer-chain unsaturated species, and it correlated with the increase of
insulin sensitivity.
The effect of a 3-week randomized double-blind placebo-controlled intervention
with the probiotic Lactobacillus rhamnosus (LGG) on serum lipidomic profiles was
studied in 26 healthy adults (179).  Serum samples showed decreases in the levels of
LPCs, SMs and several PCs while TGs were mainly increased in the probiotic group.
The inflammatory marker IL-6 was associated with changes in global lipidomic
profiles, especially with LPC(20:4).
The effect of coffee consumption on human lipidome was studied with 284 male
participants (180). Coffee intake was positively associated with two classes of SMs,
one hydroxylated and the other carboxylated and negatively with acylcarnitines.
Also the concentration of total cholesterol rose with increased coffee intake, which
may induce also increases of SMs. Alternatively, the authors suggest that increased
SM species might act as scavengers of oxidative species that decreased with higher
coffee intake.
2.3 DIET IN THE MANAGEMENT OF THE METABOLIC SYNDROME
AND RELATED DISEASES
Recent randomized controlled clinical trials have demonstrated that lifestyle
interventions  are  efficacious  in  delaying  or  preventing  the  development  of  T2DM
and other risk factors for CVD (79, 80, 80, 181-185). These studies have used a
combination of increased physical activity with dietary intervention and found up
to a 58% reduction in the risk of diabetes in high-risk subjects. In the Finnish
Diabetes Prevention Study the goals of the intervention were reduction in weight of
 5%, total intake of fat < 30 E%, intake of saturated fat < 10 E%, intake of dietary
fiber  15 g per 1000 kcal and moderate exercise  30 minutes per day (181). In the
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Diabetes Prevention Program the aim was weight reduction of  7% through healthy
low calorie, low fat diet and moderate exercise for  150 min per week (182). In the
China Da Quing Diabetes Prevention Study the goal of the intervention was to
increase participants’ vegetable intake, lower their alcohol and sugar intake and
increase leisure time physical activity (183). Those who were overweight or obese
were also encouraged to lose weight.
Recently, Adamsson and colleagues investigated effects of a healthy Nordic diet on
cardiovascular risk factors in 88 hypercholesterolemic subjects (186). The Nordic
diet  was  rich  in  high-fiber  plant  foods,  fruits,  berries,  vegetables,  whole  grains,
rapeseed oils, nuts, fish and low-fat milk products, but low in salt, added sugars and
saturated fats. After a 6-week consumption of healthy Nordic diet blood lipid
profile, insulin sensitivity and systolic blood pressure improved at clinically
relevant levels. Despite the ad libitum nature of the diet, body weight decreased
significantly (4%) during the 6-week intervention period.
2.3.1 Whole grain
The U.S. Food and Drag Administration (FDA) defines whole grains as consisting of
the  intact,  ground,  cracked,  or  flaked  fruit  of  grains  whose  principal  components,
the starchy endosperm, germ and bran, are present in the same relative proportions
as they exist in the intact grain (187). The U.S. Whole Grain Council defines whole
grains as follows “Whole grains or foods made from them contain all the essential
parts and naturally occurring nutrients of the entire grain seed” (188). There are
much  data  available  on  the  health  benefits  of  whole  grain  intake,  but  in  those
studies the concept of whole grain has been broader than definitions above (187).
Whole grain food consumption has been linked to reduced risk of MetS (189-191),
T2DM (192-198), CVD (193, 194, 199, 200) and certain cancers (201-203). Moreover,
positive effects of whole grain foods on weight maintenance and obesity (204-207),
hypertension (208) and bowel function (209, 210) have been reported. Whole grains
are rich in many components, including dietary fiber, resistant starch,
oligosaccharides, unsaturated fat, plant stanols and sterols, antioxidant nutrients,
minerals, vitamins and phyto-estrogens, which may mediate its protective effects
against chronic diseases (211). Summary of dietary interventions related to whole
grain food consumption and glucose and insulin metabolism is presented in Table 2.
There are several possible mechanisms by which whole grain food may affect lipid
metabolism. First, soluble fiber has hypocholesterolemic effects, which are largely
based on its ability to increase fecal bile acid excretion (212-214). Second, whole
grains are rich sources of fermentable carbohydrates, including dietary fiber,
resistant starch and oligosaccharides (211). Undigested carbohydrates reaching the
colon are fermented by intestinal microflora to short-chain fatty acids (acetate,
propionate and butyrate), which reach the liver by the portal vein and modulate
hepatic cholesterol, fatty acid and TG synthesis resulting reduction in plasma TG,
phospholipid and cholesterol levels (215-219).  Furthermore, some bacteria may
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interfere with cholesterol metabolism by reducing intestinal cholesterol and bile acid
absorption (218, 219). Moreover, short-chain fatty acids can increase leptin
production (220, 221). Leptin, originally termed the “anti-obesity hormone”, is an
adipocyte-secreted hormone acting on the brain to regulate energy homeostasis
(222). Leptin also stimulates triglyceride depletion in white adipose tissue without
increasing free fatty acid release, thus favoring fatty acids versus glucose as a fuel
source (223).
T
ab
le
 2
. 
E
ff
ec
t 
of
 c
ar
b
oh
yd
ra
te
-m
od
if
ie
d
 d
ie
ts
 (
in
cr
ea
se
d
 w
h
ol
e
 g
ra
in
 f
oo
d
s 
or
 d
ie
ta
ry
 f
ib
er
 o
r 
de
cr
ea
se
d
 g
ly
ce
m
ic
 i
n
d
ex
) 
on
 g
lu
co
se
 a
n
d
in
su
lin
 m
et
a
b
ol
is
m
 i
n
 h
u
m
an
 s
u
b
je
ct
s
R
e
fe
re
n
c
e
 
P
o
p
u
la
ti
o
n
D
e
s
ig
n
 a
n
d
d
u
ra
ti
o
n
D
ie
t
R
e
s
u
lt
s
(2
2
4
)
3
1
6
 o
ve
rw
ei
g
h
t 
m
en
an
d
 w
o
m
en
3
 g
ro
u
p
s,
 p
ar
a
lle
l,
 1
6
w
e
e
ks
6
0
 g
 w
h
o
le
 g
ra
in
/d
ay
, 
o
r 
6
0
 g
 w
h
o
le
 g
ra
in
/d
ay
fi
rs
t 
8
 w
e
e
k
s 
a
n
d
 1
2
0
 g
 w
h
o
le
 g
ra
in
/d
ay
 n
e
x
t 
8
w
ee
ks
, 
o
r 
co
n
tr
o
l 
d
ie
t 
w
it
h
 n
o
 c
h
an
g
e
s
N
o
 e
ff
e
ct
 o
n
 F
P
G
, 
in
su
lin
 o
r 
m
od
if
ie
d
 q
u
a
n
ti
ta
ti
v
e
 i
n
su
lin
se
n
si
ti
v
it
y 
ch
e
ck
 i
n
d
ex
(2
2
5
)
7
 w
o
m
en
 w
it
h
 I
G
T
 a
n
d
h
is
to
ry
 o
f 
g
e
st
at
io
n
al
d
ia
b
e
te
s
2
 g
ro
u
p
s,
 c
ro
ss
-o
ve
r,
3
 w
e
e
ks
 p
e
r
in
te
rv
e
n
ti
o
n
lo
w
 G
I 
+
 h
ig
h
 D
F 
b
re
a
d
s,
 o
r 
h
ig
h
 G
I 
+
 l
o
w
 D
F
b
re
a
d
s
A
U
C
 f
o
r 
in
su
lin
 d
e
cr
ea
se
d
 a
ft
e
r 
lo
w
 G
I+
 h
ig
h
 D
F 
b
re
a
d
s
(2
2
6
)
1
8
 m
en
 a
n
d
 w
o
m
en
w
it
h
 T
2
D
M
2
 g
ro
u
p
s,
 c
ro
ss
-o
ve
r,
4
 w
e
e
ks
 p
e
r
in
te
rv
e
n
ti
o
n
H
ig
h
 C
H
 +
 l
ow
 G
I 
+
 h
ig
h
 D
F,
 o
r 
lo
w
 C
H
 +
 h
ig
h
G
I 
+
 l
o
w
 D
F
se
lf
-m
o
n
it
o
re
d
 b
lo
o
d
 g
lu
co
se
s 
im
p
ro
ve
d
, 
p
o
st
p
ra
n
d
ia
l
g
lu
co
se
 a
n
d
 i
n
su
lin
 d
e
cr
e
a
se
d
 a
n
d
 l
at
e
 p
o
st
p
ra
n
d
ia
l
h
y
p
og
ly
ce
m
ia
 r
ed
u
ce
d
 a
ft
e
r 
h
ig
h
 C
H
 +
 l
ow
 G
I 
+
 h
ig
h
 D
F
d
ie
t
(2
2
7
)
1
1
 m
en
 a
n
d
 w
o
m
en
w
it
h
 I
FG
 o
r 
T
2
D
M
2
 g
ro
u
p
s,
 c
ro
ss
-o
ve
r,
6
 w
e
e
ks
 p
e
r
in
te
rv
e
n
ti
o
n
p
re
-g
er
m
in
a
te
d
 b
ro
w
n
 r
ic
e 
o
r 
w
h
it
e 
ri
ce
FP
G
 d
e
cr
e
a
se
d
 a
ft
er
 b
ro
w
n
 r
ic
e
 d
ie
t
(2
2
8
)
1
1
 o
ve
rw
ei
g
h
t 
o
r 
o
b
e
se
m
e
n
 a
n
d
 w
o
m
e
n
2
 g
ro
u
p
s,
 c
ro
ss
-o
ve
r,
6
 w
e
e
ks
 p
e
r
in
te
rv
e
n
ti
o
n
w
h
o
le
 g
ra
in
s 
o
r 
re
fi
n
e
d
 g
ra
in
s
fa
st
in
g
 i
n
su
lin
 d
e
cr
ea
se
d
  
a
ft
e
r 
w
h
o
le
 g
ra
in
 d
ie
t
(2
2
9
)
3
1
 o
b
e
se
 m
en
 a
n
d
w
o
m
en
 w
it
h
 I
FG
2
 g
ro
u
p
s,
 c
ro
ss
-o
ve
r,
4
 w
e
e
ks
 p
e
r
in
te
rv
e
n
ti
o
n
w
h
o
le
 g
ra
in
 b
a
se
d
 d
o
u
b
le
-f
e
rm
e
n
te
d
 d
ie
ta
ry
p
ro
d
u
ct
 o
r 
co
m
m
e
rc
ia
l 
m
e
al
 r
e
p
la
ce
m
e
n
t
p
ro
d
u
ct
a
ft
e
r 
a
d
ju
st
in
g
 f
or
 w
e
ig
h
t 
lo
ss
, 
fa
st
in
g
 i
n
su
lin
 a
n
d
 H
O
M
A
-
IR
 d
e
cr
e
a
se
d
 a
ft
e
r 
w
h
o
le
 g
ra
in
 p
ro
d
u
ct
(2
3
0
)
3
0
 o
ve
rw
ei
g
h
t 
m
en
 a
n
d
w
o
m
en
2
 g
ro
u
p
s,
 c
ro
ss
-o
ve
r,
6
 w
e
e
ks
 p
e
r
in
te
rv
e
n
ti
o
n
w
h
o
le
 g
ra
in
s 
o
r 
re
fi
n
e
d
 g
ra
in
s
n
o
 e
ff
ec
t 
o
n
 F
P
G
 a
n
d
 i
n
su
lin
 o
r 
p
er
ip
h
e
ra
l 
in
su
lin
se
n
si
ti
v
it
y
(2
3
1
)
2
0
 p
o
st
-m
en
o
p
au
sa
l
w
o
m
en
2
 g
ro
u
p
s,
 c
ro
ss
-o
ve
r,
8
 w
e
e
ks
 p
e
r
in
te
rv
e
n
ti
o
n
h
ig
h
 f
ib
e
r 
ry
e
 b
re
ad
 a
n
d
 w
h
it
e
 w
h
e
a
t 
b
re
ad
im
p
ro
ve
d
 a
cu
te
 i
n
su
lin
 r
e
sp
o
n
se
 a
ft
e
r 
h
ig
h
 f
ib
e
r 
ry
e
b
re
a
d
A
U
C
, 
ar
ea
 u
n
d
e
r 
th
e
 c
u
rv
e
; 
C
H
, 
ca
rb
o
h
y
d
ra
te
; 
D
F,
 d
ie
ta
ry
 f
ib
e
r;
 F
P
G
, 
fa
st
in
g
 p
la
sm
a
 g
lu
co
se
; 
G
I,
 g
ly
ce
m
ic
 i
n
d
e
x
; 
IF
G
, 
im
p
ai
re
d
 f
a
st
in
g
 g
lu
co
se
; 
IG
T
, 
im
p
ai
re
d
 g
lu
co
se
to
le
ra
n
ce
; 
T
2
D
M
, 
ty
p
e 
2
 d
ia
b
et
e
s
22
23
2.3.1.1 Rye
Whole-meal sour rye breads are an essential part of the Finnish diet.  Approximately 85 %
of  Finnish males  and females  include rye  bread in  their  diet  and the  average amount  of
consumption is 105 g/day in men and 67 g/day in women (232). Rye bread induces
postprandially lower insulin response than mixed wheat bread (233-236) (Figure 5). Rye
products also tend to produce more stable glucose curves that have lower glucose peak
and remain above fasting for a longer time (235). Total fiber content does not explain the
lower postprandial insulin response to rye bread than to wheat bread, but structural
differences between rye and wheat breads might (234). A rye bread breakfast induces less
feeling of hunger both before and after lunch than a wheat bread breakfast (237).
A twelve-week consumption of rye bread and pasta enhanced early insulin secretion in
persons with MetS (238). That might be due to repeated lower postprandial insulinemic
response,  which allows -cell  function to  recover,  or  decreased insulin  resistance,  which
improves early insulin secretion over the long term (239). Rye bread and pasta diet also
modulates the gene expression profile in abdominal subcutaneous tissue by decreasing
genes regulating insulin signaling and apoptosis (240).
Four week consumption of rye bread as part of usual diet decreases serum total and LDL
cholesterol  concentrations  in  men  by  average  8%,  but  do  not  alter  cholesterol  in  women
(241). The decrease in total and LDL cholesterol are dependent of the amount of rye bread
consumed. The mechanism might be related to decreased cholesterol absorption, which
was seen after a twelve-week consumption of rye-bread pasta diet (242). Good compliance
with consumption of a relatively large amount of rye bread in the usual diet indicates that
rye bread may offer a practical dietary means of improving insulin metabolism in men and
women, and reducing serum cholesterol concentration in men.
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B
Figure 5. Plasma glucose (A) and insulin (B) concentrations in healthy subjects after ingestion
of the wheat bread, whole kernel rye bread, wholemeal rye bread, wholemeal rye crispread.
Values are means, n= 20. * p< 0.05 (233).
2.3.2 Fish and long chain n-3 PUFAs
Omega-3 (or n-3) fatty acids are polyunsaturated fatty acids in which the first double bond
counting  from  the  methyl  end  is  at  position  3.  Major  n-3  fatty  acids  include  -linolenic
acid (ALA 18:3n-3), eicosapentaenoic acid (EPA 20:5n-3) and docosahexaenoic acid (DHA
22:6n-3). Preformed EPA and DHA are best obtained from fatty fish or fish-oil
supplements.  ALA  is  obtained  from  certain  seed  oils,  but  only  a  small  percentage  is
converted to EPA, and further transformation to DHA is very low. ALA is one of the two
essential fatty acids, since it and linoleic acid (LA 18:2n-6)  cannot  be  synthesized  by
A
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mammals, because the necessary enzymes to place double bond at the n-3 or n-6 positions
are absent (58, 243).
2.3.2.1 Fish in the prevention of CHD
The epidemiological evidence of the beneficial effects of consumption of fish and marine
origin n-3 fatty acids on the prevention of CHD progression, events and mortality is strong
(58, 244-247, 247-256). The benefit seems to be dose dependent. In the meta-analysis of
Harris and colleagues, the average intake of EPA and DHA associated with the lowest risk
for death from CHD was 496 mg/d (257). In a population with low fish consumption,
already consumption of 230 mg of EPA + DHA per day in the form of fish decreases risk
for fatal CHD for 49% compared to those with the lowest consumption (40 mg/day) (245).
Also in Japan, where the average fish consumption is around 100 g/day, strong inverse
associations existed between dietary intake of marine origin n-3 fatty acids and risk of
definite myocardial infarction and nonfatal coronary events (249). This study indicates that
compared with modest fish intake high intake (180 g/day) may further reduce the risk of
initial CHD in individuals without CHD at baseline. A meta-analysis of cohort studies
showed that each 20 g/d increase in fish intake was related to a 7% lower risk of CHD
mortality (249). Mozaffarian and Rimm estimated cardio-protective intakes by combining
epidemiologic  and interventional  studies  from around the  word done with both healthy
volunteers and CHD patients and suggested an intake of about 250 mg of EPA and DHA
daily (258).
The American Heart Association (AHA) recommends at least two servings per week of
(preferably oily) fish (259). That would provide close to 400 mg/d of EPA + DHA. For
patients with documented CHD the recommendation of AHA is 1 g/day day of EPA +
DHA. Although much research has been focused on this area during past three decades,
there is no absolute consensus of the appropriate dose needed to achieve beneficial
reduction in cardiovascular events (260). Moreover, primary cardio-protective effects have
not been seen in all clinical trials (261, 262).
Proposed mechanisms on how fish oil prevents CHD and cardiac deaths include
antiarrythmic effects (263, 264), inhibition of platelet aggregation (265, 266), reduction of
blood viscosity (266), suppression of leukotriene formation (267), inhibition of endothelial
cell proliferation (268), plaque stabilization (269, 270) and reduction of insulin resistance
(271), triglyceride (58) and fibrinogen(272) concentrations, blood pressure (273) and heart
rate (274).
2.3.2.2 Fish in the prevention of type 2 diabetes
Some epidemiological studies have demonstrated associations between plasma or dietary
n-3 long-chain polyunsaturated fatty acids (PUFA) and lower prevalence of insulin
resistance and T2DM (275-278). However, these associations have not seen in all studies
(279, 280) and clinical trials involving n-3 PUFA-enriched diets have led to conflicting
results (Table 3) (275, 281). The mechanism behind the possible beneficial effect of n-3
PUFA on glucose metabolism is poorly understood. The evidence so far points to the roles
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of insulin receptor signaling (282), inflammation (283, 284), cell membrane fatty acid
composition (285, 286), circulating hormones and adipocytokines (281), or G protein-
coupled receptor 120 (287). Effects of EPA and DHA on glucose and insulin metabolism
seen in clinical trials have been collected to Table 3. On the other hand, also adverse effects
of high-dose fish oil supplementation on glucose metabolism have been observed in type 2
diabetic patients, including increased gluconeogenesis and impaired insulin secretion,
which may lead to further deterioration of glucose homeostasis (288-290). High-dose fish
oil supplementation could also increase LDL cholesterol concentration (KANWU),
especially in apoE4 genotype carriers (291).
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2.3.3 Berries
Berries are rich sources of vitamins, minerals, fiber and polyphenols, which are a large and
heterogenous group of phytochemicals including flavonoids, phenolic acids, anthocyanins
and resveratrol (304, 305).  As antioxidants, polyphenols may protect cell constituents
against oxidative damage and, therefore, limit the risk of various degenerative diseases
associated to oxidative stress (306-308). Numerous studies on animal models have shown
that, when added to the diet, polyphenols limit the development of cancers, CVD,
neurodegenerative diseases, diabetes and osteoporosis, but the effects in humans are not
that clear (306, 309). However, epidemiological evidence suggests the existence of a
negative correlation between consumption of polyphenols or foods and beverages rich in
polyphenols and the incidence of CVD (310-314) and certain cancers (315-317), but not so
clearly of T2DM (318-321). A major difficulty with these correlative studies is the extreme
complexity of polyphenols in foods and beverages, since several hundreds of phenolic
compounds have been described (322).
There is some supportive evidence for beneficial effects of fruit polyphenols on CVD risk,
particularly with respect to lowering blood pressure, inhibition of platelet aggregation and
increasing vascular function (323). Effects have seen especially with fruits containing
relatively high concentrations of flavonols, anthocyanins and procyanidins, including
berries (323). Human intervention studies using berries or anthocyanin extracts have also
demonstrated improvements in LDL oxidation, lipid peroxidation, total plasma
antioxidant capacity and dyslipidemia (324). Finnish single-blind, randomized, placebo-
controlled intervention trial, where middle-aged subjects (n=72) with cardiovascular risk
factors consumed daily 2 portions of combination of bilberries, lingonberries, blackcurrant,
strawberry and raspberry or control products for 8 weeks, showed favorable changes in
platelet function, HDL cholesterol and blood pressure (325). Interestingly, especially
related to anti-platelet effects, combination of polyphenolic compounds, despite lower
concentrations of polyphenols, causes greater effects than isolated individually used
polyphenols (326, 327).
In  animal  models  and  in  a  limited  number  of  human  studies  carried  out  so  far,
polyphenols have attenuated postprandial glycemic responses and fasting hyperglycemia,
and improved acute insulin secretion and insulin sensitivity (305, 328-331). Possible
mechanism include inhibition of carbohydrate digestion (332, 333) and glucose absorption
in the intestine (334), stimulation of insulin secretion (335, 336), modulation of glucose
release from the liver (337, 338), activation of insulin receptors and glucose uptake in the
insulin-sensitive tissues (339-341), and modulation of intracellular signaling pathways and
gene expression (337, 339, 340).
2.3.3.1 Bilberry
Bilberries are particularly abundant in polyphenols, especially anthocyanins
(>500mg/100g) (342). Anthocyanin profiles of bilberries and blueberries have similarities,
but total content of anthocyanins is substantially higher in bilberry than in blueberry (342).
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A recent controlled randomized trial showed that consumption of freeze-dried blueberry
beverage (approximately 350 g fresh blueberries per day) for 8 wk decreased systolic and
diastolic blood pressures, plasma oxidized LDL and lipid peroxidation in 48 obese men
and women (343). Blueberry supplementation did not affect fasting serum glucose, insulin
or lipid profiles, which may be due the fact that participants had normal levels of glucose,
insulin and lipids (except low HDL cholesterol). Dietary consumption of blueberry
polyphenolics has demonstrated significant protection against free radicals and oxidative
stress also within red blood cells in vivo (344).
In another human study, 32 obese, insulin-resistant subjects were randomized to consume
either a smoothie containing 45 g blueberry bioactives (equivalent to approximately 335 g
fresh whole blueberries per day) or a smoothie of equal nutritional value without added
blueberry  bioactives  for  6  wk.  Insulin  sensitivity,  measured  by  a  high-dose
hyperinsulinemic-euglycemic clamp, was enhanced in the blueberry group without
significant changes in adiposity, energy intake and inflammatory biomarkers (345).
Anthocyanin treatment of human adipocytes has been shown to regulate adipocytokine
gene expression, which possibly ameliorates adiposity function related with obesity and
diabetes (346).
Table 4. The  content  of  the  focal  nutrients  in  bilberry  compared  to  strawberry,  orange  or
tomato
Bilberry Strawberry Orange Tomato
Energy (kcal/100g) 44 47 47 23
Sugars (g/100g) 6.4 8.4 8.9 3.3
Total fiber (g/100g) 3.3 1.9 2.1 1.4
C-vitamin (mg/100g) 15 60 51 14.1
E-vitamin (mg/100g) 1.9 0.6 0.4 0.7
Folate (g/100g) 11.5 35.6 26.5 11.6
Total antioxidants (mmol/l) 8.23 2.17 1.14 0.31
Source: FINELI, Finnish food composition database (National Institute for Health and Welfare),
antioxidants (347).
2.4 SUMMARY OF THE REVIEW OF THE LITERATURE
This review of the literature indicated that metabolomics and lipidomics could be
valuable tools for nutrition science even though seminal applications are still scarce.
Metabolomics approaches allow characterization of the effects of a nutrient, a food item
or a diet with much more precision than classical approaches in nutrition research, which
may help elucidate the complex relationship between nutrition and metabolism, and the
role that dietary components play in health maintenance and disease development.
Diet plays an important role in the prevention of chronic diseases such as CVD and
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T2DM. Whole grain foods, fish and berries, basic components of the Nordic diet, may be
essential components also in a cardiovascular- and diabetes-protective diet. However,
mechanisms by which these foods affect in human body are not completely understood
and interest to study synergistic effects of these foods have been raised just recently. To
assess the effects of consumption of whole grain foods, fish and berries for prevention of
MetS, T2DM and CVD, human trials with well-defined diets and controlled study designs
combined with novel metabolomics approaches and computational tools are needed.
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3 Aims of the study
The purpose of the study was to apply metabolomics platforms to study the effects of
dietary interventions in subjects at risk for MetS or CVD.  The specific research questions
were what kind of changes in metabolomic and especially lipidomic profiles were caused
by
1) Low (rye bread and pasta) or high (oat-wheat bread and potato) insulin response
carbohydrates (Study I, Fungenut)
2) Lean fish or fatty fish (Study II, Fish)
3) High-fiber rye bread or white wheat bread (Study III, Bread 2)
4) Low  insulin  response  grain  products  with  fish  and  bilberries  or  low  insulin
response grain products alone (Study IV, Sysdimet-HealthGrain).
Furthermore, in Study I we also aimed to assess dependencies between the dietary
modified lipid profiles and specific gene expression pathways in adipose tissue. In Study
IV the  aim  was  to  evaluate  the  effect  of  the  intervention  diet  on  glucose  and  insulin
metabolism in addition to changes in the lipidomic profile.
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4 Subjects and methods
4.1 STUDY POPULATIONS AND DESIGNS
All studies included middle-aged or older Finnish persons. Except for the Bread 2 study,
both males and females were included. Summary of the clinical characteristics at baseline
of the studies is presented in Table 5. Based on mean BMIs, subjects were overweight or
obese  in  all  studies,  even  though  Fish  study  and  Bread  2  study  included  also  normal
weight subjects. Serum total and LDL cholesterols were at least slightly elevated in all
studies, except for the Fish study, where all subjects were using statins. Fasting plasma
glucose was elevated ( 5.6 mmol/l) in all studies, apart from the Bread 2 study.
4.1.1 Fungenut study (Study I)
The  Functional  Genomics  and  Nutrition  Study  (Fungenut)  consisted  originally  of  53
overweight or obese men and women. The Fungenut population was a subpopulation of a
previously reported dietary intervention study (238).  The inclusion criteria were 40-70
years of age and a body mass index (BMI) between 26 and 40 kg/m2. The subjects had to
meet the National Cholesterol Education Program criteria for MetS (at least 3 of the
following 5 conditions: 1) a waist circumference > 102 cm for men and > 88 cm for women,
2) fasting serum triacylglycerol concentration > 1.7 mmol/l, 3) fasting HDL cholesterol
concentration < 1.0 mmol/l for men / < 1.2 mmol/l for women, 4) impaired fasting glucose;
plasma glucose between 6.1 and 6.9 mmol/l, 5) blood pressure > 130/85 mmHg or use of
blood pressure medication). Subjects were excluded if they were diagnosed with diabetes,
receiving any cholesterol lowering medication, or using cortisone regularly. The Fungenut
study was completed by 47 individuals. Of these 47 subjects, 20 were included in the
transcriptomics study of adipose tissue based on the availability of both pre- and post-
intervention samples and the purity of the samples (240). These subjects were included in
the present metabolomics study as well (Table 5).
The study design had two parallel groups and consisted of a 4-week baseline period and a
12-week intervention period (Figure 6). The subjects were randomly assigned according to
gender, median age and two-hour plasma glucose to an oat and wheat bread and potato
(OWP) group and a rye bread and pasta (RP) group. Blood samples for metabolomics and
other biochemical measurements were drawn and adipose tissue biopsies were performed
at baseline and at the end of the 12-week intervention period.
The aim was to cover more than 25% of the daily energy intake with the test breads. About
50% of the daily bread consumption in OWP group and RP group was to be oat bread and
endosperm rye bread, respectively, made by the VTT Technical Research Centre of
Finland. The fibre content of the oat bread and endosperm rye bread was almost equal in
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order to achieve similar fibre intake from breads. The main difference between the diets
was the postprandial insulin response: rye breads and pasta produced lower insulin
response than oat-wheat breads and potatoes, where as the postprandial glucose response
did not differ between the diets (233). The subjects in the RP group were advised to use at
least one portion of pasta at least three times a week. The subjects in the OWP group were
advised to use mainly potatoes as part of warm dishes. Otherwise, the diet was to remain
unchanged. Especially the amount and type of fat and cold cuts eaten with bread was
advised to be kept unchanged during the study.
Compliance with the diets and the dietary intake was assessed with daily records of bread,
potato,  pasta  and  other  cereal  consumption  and  with  4-days  food  records  kept  twice
during weeks 4-8.
4.1.2 Fish study (Study II)
Altogether 44 subjects, identified from the discharge lists of the Kuopio University
Hospital, were screened for the eligibility for the FISH -study, and 33 subjects were
accepted (Table 5).  All of them had acute myocardial infarction or unstable ischemic
attack during the previous 3-36 months. To be included in the study, the subjects had to
have age under 70 years, normal sinus rhythm, fasting serum triglyceride concentration 
3.5 mmol/l, fasting serum cholesterol concentration  8 mmol/l, BMI 18.5-30 kg/m2, fasting
plasma glucose concentration  7.0 mmol/l and they had to use beta blockers. Subjects
were excluded if they used other antiarrhythmic medications than beta blockers or
psychotropic drugs, were diagnosed with diabetes, atrial fibrillation, inflammatory bowel
disease  or  abnormal  liver,  thyroid  or  kidney  function  or  used  excessive  amounts  of
alcohol. Subjects who reported use of fish oil supplements or high fish intakes (>3
meals/week) during the last three months were excluded from the study. All subjects were
using statins in addition to beta blockers, and 88% of subjects were also using
acetosalisylic acid, 45% an ACE inhibitor, 39% an oral anticoagulant, 27% a calcium
antagonist and 27% a nitrate.
The study was an 8-week controlled, parallel intervention (Figure 6). The subjects were
randomized to one of the following groups: fatty fish group (n=11), lean fish group (n=12)
or control group (n=10). Blood samples for lipidomics and other biochemical
measurements were drawn at baseline and at the end of the 8-week intervention period.
Subjects in the fatty fish and lean fish groups were advised to consume fish 100-150 g/meal
at least four times a week.  Subjects in the fatty fish group consumed e.g. salmon, rainbow
trout,  Baltic  herring,  whitefish  and  vendace,  and  in  the  lean  fish  group  e.g.  pike,  perch,
pike-perch, saithe and cod. Subjects in the control group were instructed to consume less
than one fish meal per week and to eat meals made with lean meat (beef or pork) or
chicken  without  skin.  Otherwise  all  subjects  were  instructed  by  a  clinical  nutritionist  to
follow a diet recommended for CHD patients (259).  They were advised to avoid sources
of saturated fat like cream and butter in food preparation. Use of fish oil supplements was
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not allowed in any of the groups. Subjects continued to use the medications prescribed by
their physicians.
Subjects' habitual dietary intake was estimated by a 4-day food record (consecutive days, 3
weekdays and one weekend day) at the baseline. Dietary compliance was monitored by
using a 7-day food record kept twice during the intervention (weeks 3 and 7) and with the
daily record of fish consumption.
4.1.3 Bread 2 study (Study III)
Forty-four postmenopausal women were recruited into the study by an advertisement in a
local newspaper. The inclusion criteria were a serum total cholesterol concentration of 5.0-
8.5 mmol/l, a non-HDL-cholesterol concentration of 3.5-6.5 mmol/l, a serum total
triglyceride concentration of  < 2.5 mmol/L, and BMI of 20-33 kg/m2. Use of lipid-lowering
drugs, laxatives, or corticosteroid medication was not allowed. Subjects diagnosed with
diabetes mellitus were excluded. Post-menopausal status was confirmed by measuring
serum follicle-stimulating hormone concentration. Thirty-nine subjects completed the
study (Table 5).
The study was carried out as a randomised cross-over study (Figure 6). The first bread
period was preceded by a 2-3 week run-in period and after that the subjects were
randomly  assigned  into  either  an  8-week  rye  bread  period  or  an  8-week  wheat  bread
period.  Between the bread periods, there was an 8-week washout period, during which
the subjects consumed their usual diet. Blood samples for metabolomics and other
biochemical measurements were drawn at the beginning and end of the rye bread period
and at the beginning and end of the wheat bread period.
The aim during the intervention was to cover a minimum of 20% of the daily energy
intake with the test breads and restrict the consumption of other cereal products to one
portion a day. No maximum amount of bread to be consumed was given, but the subjects
were advised to eat the breads in amounts which corresponded to their habitual diet. A
minimum of 4-5 portions of the test breads had to be eaten daily. The high-fibre rye bread
17% dietary fibre) was prepared by increasing the content of rye bran in the breads
which caused a major increase in the content of insoluble fibre. Seven different commercial
white-wheat breads (2.8% dietary fibre) produced from refined wheat flour were offered
during the wheat bread period. The test breads were developed at VTT and produced by
two commercial bakeries (Fazer Bakeries Ltd, Lahti, Finland and Vaasan & Vaasan Oy,
Helsinki, Finland).
Otherwise, the diet was to be maintained unchanged. Subjects were advised by a clinical
nutritionist on the practical management of the diet. Lifestyle habits, use of regular
medication, and body weight were also advised to be kept unchanged throughout the
study. The subjects were also instructed not to use foods containing plant stanols/sterols or
probiotics, or products that affect bowel function (plums, dried fruits, brans, muesli, seeds
or licorice).
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The subjects recorded daily the use of test breads and the consumption of other cereal
products. Four-day food records including one weekend day (consecutive days) were kept
during the run-in period and during the weeks 4-6 in both bread periods.
4.1.4 Sysdimet study (Study IV)
Altogether 131 subjects were recruited into the study by an advertizement in a local
newspaper. The inclusion criteria were age 40-70 years, impaired glucose metabolism
(fasting plasma glucose 5.6-6.9 mmol/l or 2-hour glucose 7.8-11.0 mmol/l during an OGTT)
and two of the following: BMI 26-39 kg/m2, waist circumference  102 cm in men and  88
cm in women, serum triglycerides > 1.7 mmol/l, HDL< 1.0 mmol/l in men and < 1.3 mmol/l
in women or blood pressure  130 /   85 mmHg. Altogether 106 subjects completed the
study (Table 5), but samples for lipidomics analyses before and after the intervention were
available for 105 subjects (HealthyDiet group n=37, Whole grain enriched diet (WGED)
group n=34, control group n=34).
The study was a 12-week parallel controlled dietary intervention study (Figure 6). After a
baseline  period  of  two  weeks,  the  subjects  were  randomized  into  three  groups:
HealthyDiet (n=37), WGED (n=34) or control (n=35). Blood samples for lipidomics and
other biochemical measurements were drawn at baseline and at the end of the 12-week
intervention period.
In the HealthyDiet group, the subjects replaced their habitually used cereal products with
breads having a low postprandial glucose and insulin response, contributing up to 20-25%
of total energy intake (40% share of endosperm rye bread, 10% share of sourdough whole
meal wheat bread, and 50% share of a selection of commercial rye breads) and whole meal
pasta, which was recommended to be eaten at least 3.5 deciliter (uncooked) a week. The
fiber content (%) of the study cereal products was: endosperm rye bread 6.9, whole meal
wheat bread 6.4, commercial rye breads 10-14 and pasta 6. Besides above mentioned cereal
products, one portion of their habitually used cereal product was allowed to eat daily, for
example porridge, cereals or pastries. Subjects were also instructed to eat fatty fish meals
(100-150 g of fish /meal) three times a week. The following fish species were
recommended: salmon, rainbow trout, bream, Baltic herring, roach, vendace, white fish,
char, trout, red-fish, mackerel and anchovy.  For fish preparation, subjects were advised to
avoid sources of saturated fat, like butter and cream. Three portions of bilberries were
eaten per day. Bilberries were served as frozen, puree and dried powder. The total amount
of three portions corresponded to 300 grams of fresh bilberries. Another habitually used
berry portion was allowed 3-4 times per week.
The WGED group consumed same cereal products as HealthyDiet group. Subjects in the
WGED group were asked not to change their fish and berry consumption. In the control
group the subject replaced their habitually used breads with refined wheat breads (dietary
fiber 3-4.3 g/100g) and other cereal products, like porridge or pasta, with low fiber
products (<6 g/100g dietary fiber). Rye products were allowed be eaten maximum 1-2
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portions a day. The intake of bilberries was not allowed and other berries were allowed to
be eaten maximum of 3-4 times per week maximum of 1 deciliter at a time. Fish was
allowed to be eaten no more than once a week.
Subjects recorded daily the use of the test breads (all groups), pasta (HealthyDiet and
WGED), oat biscuits (WGED), bilberries (HealthyDiet), and fish (HealthyDiet). Four-day
food records that included one weekend day (consecutive days) were kept during the run-
in period and three times during the intervention period in all groups.
4.1.5 Approval of Ethics Committee
In all  studies subjects volunteered to the study and gave their written informed consent.
Fungenut study was approved by the Ethics Committee of the University of Kuopio and
Kuopio University Hospital, Fish and Sysdimet studies by the Research Ethics Committee,
Hospital District of Northern Savo and Bread 2 study by the Ethics Committee of the
Kuopio University Hospital. All of the interventions were performed in accordance with
Helsinki Declaration.
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Figure 6. Summary of study designs
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4.2 METHODS
The methods are summarized in the table 6.
Table 6. Summary of the methods
Method Study I
Fungenut
Study II
Fish
Study III
Bread 2
Study IV
Sysdimet
Anthropometrics x x x x
Blood pressure x x x x
Fasting glucose and insulin x x x x
OGTT1 x
Routine clinical lipids x x x x
Fatty acids x x x
Lipidomics x x x x
GCxGC TOF2 x
Branched chain amino acids x
Adipose tissue gene expression and
pathway analyses
x
1Oral glucose tolerance test, 22-dimensional gas chromatography coupled to time-of-flight mass
spectrometry
4.2.1 Anthropometric measurements and blood pressure
Height and weight were measured with regularly calibrated devices in light clothing, and
the body mass index (BMI) was calculated weight (kg) / height (m)2.  Waist circumference
was measured halfway between the lowest rib and the iliac crest. Both weight and waist
circumferences were measured in a fasting state.
Systolic and diastolic blood pressure was measured in sitting position using a standard
sphygmomanometer after 10 min rest. The mean value was calculated from the two
measurements obtained.
4.2.2 Biochemical measurements
4.2.2.1 Glucose and insulin
Blood samples were drawn from an antecubital vein after a 12-h fast. In the Fungenut
study, plasma glucose was analyzed by the glucose dehydrogenase photometric method
(Merck Diagnostica, Darmstadt, Germany) and KonePro Clinical Chemistry Analyser
(Thermo Clinical Labsystems; Konelab, Vantaa, Finland). In the Bread 2 the enzymatic
photometric method (Granutest 100; Merck, Damstadt, Germany) with a Kone Specific
Clinical  Analyser  (Kone  Ltd,  Espoo,  Finland)  was  used.  In  the  Fish  and  the  Sysdimet
studies plasma glucose was analyzed by using Konelab 20XTi Clinical Chemistry
Analyzer and Enzymatic photometric (glucose hexokinase) method (Konelab System
Reagents, Thermo Fisher Scientific, Vantaa, Finland).
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In the Fungenut and Fish studies, serum insulin was analysed by a chemiluminescent
immunoassay (ACS 180 Plus Automated Chemiluminescence System: Bayer Diagnostics,
Tarrytown, NY). In the Bread 2 study, a radioimmunoassay method was used (Phadaseph
Insulin RIA 100; Pharmacia Diagnostica, Uppsala, Sweden). In the Sysdimet study serum
insulin concentration was analyzed with a chemiluminescent immunoassay (Advia
Centaur  Immunoassay  System,  Siemens  Medical  Solution  Diagnostics,  Tarrytown,  NY,
USA).
For  the  2-h  OGTT,  a  fasting  blood  sample  was  drawn,  after  which,  the  subjects  drank  a
glucose solution (75 g glucose / 3 dl) within 3 min. Blood samples were drawn through a
catheter 30, 60, 120 min after the start of glucose solute ingestion for the measurement of
plasma glucose and insulin concentrations. The glucose and insulin areas under the curve
(AUCs)  were  calculated.  Disposition  index  (DI)  was  calculated  as  a  product  of
insulinogenic index (IGI) and quantitative insulin sensitivity check index (QUICKI), which
were  calculated as  following:  IGI=  (insulin  30  min -  insulin  0  min,  pmol/L)  /  (glucose  30
min – glucose 0 min, mmol/L), and QUICKI= 1/(lg10(insulin 0 min, mU/L)+lg10(glucose 0
min,  mg/dl)).  Homeostasis  model  of  insulin  resistance  (HOMA-IR)  was  calculated  as
following: (fasting glucose mmol/l * fasting insulin mU/L) / 22.5.
4.2.2.2 Routine clinical lipids
In the Fungenut study, serum total and HDL cholesterol and triglycerides were measured
by enzymatic photometric methods with commercial kits [Cholesterol CHOD-PAP (Roche
Diagnostics, Mannheim, Germany) and Konelab HDL-Cholesterol and Konelab
Triacylglycerols  (Thermo Clinical  Labsystems Oy),  respectively]  and a  Kone Pro Clinical
Chemistry Analyzer (Thermo Clinical Labsystems Oy). LDL cholesterol was calculated
(50).
In the Bread 2 study, lipoproteins were separated by ultracentrifugation for 18 h at a
density of 1.006 kg/L to remove the VLDL cholesterol fraction. HDL cholesterol in the
infranatant was separated from LDL cholesterol by precipitation of LDL cholesterol. LDL
cholesterol was calculated as the difference between the mass of cholesterol in the
infranatant and HDL cholesterol.  Serum total cholesterol  and triglyceride concentrations
were measured by enzymatic colorimetric method with commercial kits (Monotest
Cholesterol and Triglyceride GPO-PAP, Boehringen Mannheim GmbH Diagnostica,
Mannheim Germany) using automated instrument  (Kone Specific Clinical Analyzer, Kone
Ltd, Espoo, Finland).
In the Fish and Sysdimet studies concentrations of serum total, LDL and HDL cholesterol
and triglycerides were analyzed using commercial kits (981813, 981656, 981655
(Fish)/981823 (Sysdimet) and 981786, respectively, Thermo Electron Corporation, Vantaa,
Finland)  and  Thermo  Fisher  Konelab  20XTi  Analyzer  (Thermo  Electron  Corporation,
Vantaa, Finland).
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4.2.3 Fatty acids
Sample preparation
Serum samples (40 μl) in the Fungenut study and plasma samples (50 μl) in the Fish study
were diluted with 20 μl NaCl (0.15 M, 0.9%) and extracted by a mixture of chloroform and
methanol (2:1, 200 μl in the Fungenut study and 100 μl in the Fish stydy ) after addition of
an internal standard (20 μl,  heptadecantrienoate TG C17:0, 583 mg/l in the Fungenut
study and  TG C17:0 500 mg/l + FFA C17:0 500 mg/l in the Fish study). The mixture was
homogenized by vortexing 15 seconds in the Fungenut study and 1 min in the Fish study
and incubated 30 minutes at room temperature. Then the mixture was centrifuged at
10 000 RPM for 3 minutes by an eppendorf centrifuge and the lower layer was separated
and evaporated into dryness under nitrogen flow. The residue was dissolved into 700 μl
petroleum ether (boiling point 40-60° C). Bound fatty acids were transmethylated with 250
μl NaOME (sodium methoxide in dry methanol 0.5 M) by boiling at 45° C for 5 minutes.
The mixture was acidified by adding 500 μl 15% solution of NaHSO4, and in the Fish
study, evaporated petroleumether was substituted by adding 100 μl of it and fortexed. The
mixture was transferred into microtubes (glass tubes washed with 200 μl of petroleum
ether) and centrifuged 10 000 rpm for 3 min in the Fungenut study and 5 min in the Fish
study. The petroleumether layer containing fatty acid methyl esters and FFA was
separated into a glass vial, evaporated under nitrogen flow and redissolved into 50 μl
hexane (vortexed) and transferred into a glass microinsert for GC analysis.
In the Sysdimet study the sample preparation method was slightly upgraded. Lipids from
plasma samples (50 μl) were extracted by a mixture of chloroform and methanol (2:1, 400
μl) after addition of 40 μl NaCl 0.9% (0.15M) and 10 μl internal standard
(heptadecantrienoate TG C17:0 1659.24 mg/l + FFA C17:0 584.1 mg/l). The mixture was
vortexed 1 min and incubated 30 min at room temperature. The lower layer was separated
(centrifuged 10 000 rpm 5 min) and evaporated into dryness under nitrogen flow. The
transmethylation was done similarly except that evaporated petroleumether was
substituted by adding 200 μl of it and finally the fatty acid methyl esters and FFAs were
dissolved into 500 μl of hexane.
Gas chromatography
In the Fungenut and Fish studies, 2 μl aliquots were used for GC injection at 260 ° C. Split
ratio was 1:13 and the injector liner was deactivated with glass wool. The Agilent 5890
series II Gas Chromatograph equipped with a 25 meter HP-FFAP column (diameter 0.32
mm) was used. Helium was used as carrier gas at total flow of 30 ml/min. The initial oven
temperature was 70 ° C and the temperature was increased at a rate of 7° C/min until 240°
C.  The fatty acids were detected by flame ionization detector (FID) at 300 ° C.
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In the Sysdimet study, 1 μl aliquots were used for GC injection at 260 ° C (splitless). The
Agilent 7890 Gas Chromatography equipped with HP-FFAP Polyethylene Glycol TP
column (25 m x 200 μm x 0.3 μm) was used. H2 was used as the carrier gas at a total flow of
44.5 ml/min. The initial oven temperature was 70 ° C for 1.5 min and the temperature was
increased at rate of 15° C/min until 240° C.  The fatty acids were detected by flame
ionization detector at 300 ° C.
4.2.4 Lipidomics
Sample preparation
Plasma samples (10 μl) were diluted with 10 μl sodium chloride (0,9%) and 20 μl of an
internal standard mixture containing 10 lipid classes and 100 μl chloroform / methanol
(2:1) were added. The mixture was homogenized by vortexing 2 minutes and the
extraction time was around 1 hour at room temperature. After centrifugation (10000 RPM,
3 minutes),  an exact aliquot (60 μl) of the lower layer was transferred into an HPLC vial
insert and 10 μl an external standard mixture containing 3 labelled standards was added
to the lipid extract. The sample order for LC/MS analysis was randomized.
The only exceptions to this sample preparation procedure were as follows.  In the
Fungenut study, serum samples were used instead of plasma samples and the internal
standard mixture contained 11 lipid classes besides of 10. In the Fish study, half of the
lipid extract was transferred into another HPLC vial as a replicate. In the Sysdimet study,
the incubation time was reduced from 1 hour to 40 minutes.
Ultra performance liquid chromatography (UPLC) coupled with MS
Lipid extracts were analyzed on a Waters Q-Tof Premier mass spectrometer combined
with UPLC. The column was an Acquity UPLCTM BEH C18 1×50 mm with 1.7 μm particles.
Column temperature was kept at 50 °C and the temperature of the sample organizer was
set  at  10  °C.  The  binary  solvent  system  consisted  of  A.  water  (1%  1M  NH4Ac, 0.1%
HCOOH) and B. LC-MS grade isopropanol:acetonitrile (1:2.5, 1% 1M NH4Ac, 0.1%
HCOOH). The gradient started from 65% A / 35% B and reached 80% B in 2 min, 100% B in
6 minutes and remained at this level for next 7 minutes. The total run time including a 5-
min re-equilibration step was 18 min. The flow rate was 200 μl/min and the injection
volume 1.5 μl (in the Fish study 1 μl).
The data was collected in centroid form by using ESI+ mode at mass range of m/z 300-1200
and with scan duration of 0.2 sec. The voltages of the sampling cone and capillary were 45
V and 3.4 (in the Fish study 2.9 kV), respectively. The source temperature was set at 120 °C
and nitrogen was used as desolvation gas (795 L/h) at 270 °C. Reserpine (50 μg/L) was the
lock spray reference compound at a flow rate of 10 μl/min and the scan was done at 10 s
frequency.
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In the Sysdimet study the method was upgraded with the following changes. The column
was an Acquity UPLCTM BEH C18 2.1 x 100 mm with 1.7 μm particles. The ratios of
isopropanol:acetonitrile was 1:1 instead of 1:2.5 in the binary solvent system. The gradient
reached 100% B in 7 minutes instead of 6. The re-equilibration step was reduced to 4 min
from 5. The flow rate was 400 μl/min and the injection volume 2.0 μl. The voltages of the
sampling cone and capillary were 40 V and 3.0 kV, respectively. Reserpine (200 μg/L) was
the lock spray reference compound at a flow rate of 8 μl/min.
Data processing
The raw data files obtained from UPLC -MS were first converted to CDF format. Data
processing was performed using MZmine software version 0.60 in the first three studies
(32), and MZmine 2 software in the Sysdimet study. MZmine processing consisted of four
phases: 1) peaks detection, 2) aligning based on retention times and m/z values, 3) filtering
out peaks appearing in only a few samples and 4) gap filling. Quality of results was
controlled by checking that standard peaks were found.  Peaks in the accepted alignment
list were deisotoped using MATLAB in the first three studies. Any redundant peaks (i.e.,
minor peaks with the same m/z and almost the same retention time values) after
deisotoping were eliminated and the remaining peaks were identified by their m/z and RT
values.  The added standards, used for identification and quantification, were picked from
processed data according to their masses and expected retention times. Data processing
with MZmine 2 software included chromatogram building, peak deconvolution,
deisotoping, alignment, filtering and gap filling.
The normalization of lipidomics data was performed as follows: all monoacyl lipids except
cholesterol esters, such as monoacylglycerols and monoacyl-glycerophospholipids, were
normalized with PC(17:0/0:0) internal standard, all diacyl phosphocholines and SMs were
normalized with PC(17:0/17:0), the diacyl ethanolamine phospholipids were normalized
with PE(17:0/17:0), the diacyl phosphoserine phospholipids were normalized with
PS(17:0/17:0), the diacyl phosphates and phosphoglycerols were normalized with
PA(17:0/17:0), and the triacylglycerols and cholesterol esters with TG(17:0/17:0/17:0).
Unidentified species were normalized by PC(17:0/0:0) for retention time < 300 seconds,
PC(17:0/17:0) for retention time between 300s and 410s, and TG(17:0/17:0/17:0) for higher
retention times.
In the Sysdimet study the normalization was performed similarly with the exception that
PS(17:0/17:0) and PA(17:0/17:0) were not used (all diacyl lipids except ethanolamine
phospholipids were normalized with PC(17:0/17:0)) and all ceramides were normalized
with Cer(d18:1/17:0).
4.2.5 Branched chain amino acids
An internal standard with 25 μL water containing 40 μM -amino butyric acid, 5 μL water
and 25 μL acetonitrile were added to 5 μL weighted serum sample and vortexed for 15
seconds and allowed to settle for 30 minutes. After centrifugation (10000 g for 5 min) 50 μL
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sample was withdrawn and dried under nitrogen. The dried sample was redissolved in 24
μL Waters AccQ Fluor borate buffer, and 8 μL of AccQ-fluor reagent was added. Two μL
of this solution was injected.
The instrument consisted of UPLC liquid chromatography, Atlantis dC18 column (2.1x100
mm with 3 μm particles at 42oC) and M474 fluorescence detector (	ex.=250nm; 	em.=395
nm). The eluent consisted of 140 mM triethylamine (pH 5.1) and acetonitrile. A complex
gradient was run where acetonitrile concentration was increased from original 7% to 18%
during 27 minutes. The system was controlled and data was treated with Empower
software  from  Waters  Inc.  (Milford,  MA,  USA),  which  was  also  the  supplier  of  the
hardware employed.
4.2.6 GCxGC TOF metabolomics
10 μL of an internal standard labeled palmitic acid (16:0-16,16,16d3) (500 mg/L) and 400 μL
of methanol solvent were added to 30 μL of the plasma sample. After vortexing for 2 min
and incubating for 30 min at room temperature, the supernatant was separated by
centrifugation at 10,000 rpm for 5 min at room temperature. The sample was dried under
constant  flow  of  nitrogen  gas  and  silylated  with  25  μL  of  2%  Methoxyamine  HCl  in
Pyridine (MOX) (1 h, 45 °C) and N-Methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA)
(1  h,  45  °C).  5  μL  of  retention  index  standard  mixture  with  five  alkanes  (800  ppm)  was
added to the metabolite mixture.
The instrument used was a Leco Pegasus 4D GCxGC-TOF mass spectrometer with Agilent
6890N GC and Combi PAL autosampler. The instrument parameters were as follows: 1 μl
split injection 1:20; first column: RTX-5, 10 m x 180 μm x 0.20 μm; second column: BPX-50,
1.50 m x 100 μm x 0.10 μm; helium 39.6 psig constant pressure; temperature programs:
primary oven: Initial 50 °C, 1 min. -> 295 °C, 7 °C/min, 3 min, secondary oven: +20 °C
above primary oven temperature; second dimension separation time 5 s; MS measurement
45 – 700 amu, 100 spectra/s. Raw data were processed using Leco ChromaTOF software,
followed by alignment and normalisation using in- house developed software. The
metabolites were identified by using an in-house reference compound library together
with The Palisade Complete Mass Spectral Library, 600K Edition (Palisade Mass
Spectrometry, Ithaca, NY).
4.2.7 Adipose tissue biopsy and transcriptomics
In the Fungenut study, subcutaneous adipose tissue biopsies were taken under local
anesthesia. (Lidocain 10 mg/ml, Orion Pharma, Espoo, Finland) by needle biopsy after 12-
hour fasting. Samples were taken from the superficial abdominal subcutaneous adipose
tissue lateral to the umbilicus and were immediately washed twice with GIBCO®
phosphate-buffered  saline  (PBS,  Invitrogen,  Carlsbad,  CA,  USA).  Samples  for  RNA
extraction were immediately stored in RNAlater (Ambion, Austin, TX, USA) at 4°C. After
24 h, RNAlater was removed and samples were stored at -80°C until used for RNA
extraction.
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Total RNA from adipose tissue was extracted initially with TRIzol (Invitrogen) followed
by further purification with RNeasy Mini-Kit (Qiagen, Valencia,  CA). RNA isolation and
purification were performed according to the manufacturer’s instructions. RNA
concentrations and the ratio of A260 to  A280 were determined by a NanoDrop-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The integrity of the
RNA was assessed using agarose gel electrophoresis.
Synthesis of biotin-labeled complementary RNA (cRNA), hybridization to DNA
microarrays (Affymetrix HG-U133 Plus 2.0 GeneChip) and detection of hybridized cRNA
were performed according to manufacturer’s instructions (Affymetrix Inc, Santa Clara,
CA) and is reported detailed by Kallio and colleagues (240). The arrays were scanned with
the HP GeneArray Scanner 3000 (Affymetrix Inc.)
4.2.8 Statistical analyses
4.2.8.1 Analysis of clinical, metabolomics and nutritional data
Statistical analyses were performed using the SPSS statistical software (version 14.0, SPSS
Inc., Chicago, IL),  Microsoft Office Excel 2007, and R Project for Statistical Computing
version  2.4.1  in  the  Fungenut  and  Fish  studies,  version  2.6.1  in  the  Bread  2  study  and
version 2.7.2 in the Sysdimet study.
The data were expressed as mean ± SD or mean ± SEM. The normality of distributions of
the  variables  was  tested  with  the  Kolmogorov-Smirnov  test  with  Lillefor’s  significance
correction, except in the Sysdimet study, in which the normality was estimated based on
histograms. The variables with an abnormal distribution were normalized with
logarithmic transformation. A non-parametric test was used if a normal distribution was
not achieved with transformation. Fold changes for the lipids were calculated dividing the
endpoint values by the baseline values.
Paired samples t-test or Wilcoxon signed ranks test was used for comparisons within the
groups (Studies I-III). Independent samples t-test or Mann Whitney’s U-test was used for
comparisons  between  the  groups  (Study I) and General Linear Model for repeated
measurements was used to determine differences in dietary intake between the groups
(Study I). Characteristics at baseline among the groups were tested with one-way analysis
of  variance  (ANOVA)  or  
2 test when appropriate (Study II).  In  the  Fish  study  ANOVA
was also performed on lipidomics data to compare the group differences at baseline and
after the intervention. In order to correct for multiple comparisons, False Discovery Rate
(FDR) q-values (348) in the Studies I-III and FDR p-values in the Study IV were calculated.
In the Fungenut study q<0.25, Fish study q<0.05 and Bread 2 study q<0.1 and Sysdimet
study FDR p<0.05 were considered significant. For consistency, in this summary q or FDR
p<0.05 is considered significant. Spearman rank correlation was used to calculate
correlation coefficients.
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In the Fish study, a mixed model was used to assess relation between lipidomics variables
and EPA and DHA in order to get both time points into the same model. There was a high
correlation between EPA and DHA. Thus their sum (as they have a same scale) was used
in the modeling instead of EPA and DHA separately. After that they were standardized
(to have zero mean and standard deviation of 1) to get comparable standardized
regression coefficient estimates. Every transformed lipidomics variable was modeled
separately with a transformed mean variable and time as a fixed and person as a random
explanatory variables.
In  the  Bread  2  study,  so  called  rye  and  wheat  indices  were  calculated  for  each  GCxGC-
TOF/MS metabolites and for each person who had both measurements during each bread
period. Indices were calculated as following: Rij=(valij(r2)-valij(r1))/medianj(r1, r2), where Rij is
rye  index  for  person i and metabolite j, val=peak area, r2=end of bread period and  r1=
beginning of bread period.  Wheat indices were calculated similarly, but using values
during the wheat bread period.
In the Sysdimet study, linear mixed-effect models were used to analyse group differences
in the baseline and during the intervention. Selected confounding phenotypes were
included in the models (except when analysing clinical characteristics) as covariates (age,
gender, BMI, insulin and glucose), and subject identifiers were included as a grouping
random effect. Interaction term between group and intervention time-point (before or after
intervention) was used to examine group related changes during the intervention. Control
group was used as a reference group when comparing group differences. The association
of plasma EPA and DHA with glucose metabolism was tested with linear regression
model (age, gender and weight changes were included in the model). Kruskal-Wallis test
was performed in order to test differences in changes in glucose metabolism between
different plasma EPA and DHA quartiles.
4.2.8.2 Multivariate analysis of lipidomics and transcriptomics data
In the Fungenut study, partial least squares discriminant analysis (PLS/DA) (349, 350) was
utilized as a supervized modeling method using SIMPLS algorithm to calculate the model
(351). The aim was to study the changes in the lipid profiles and pathways prior to and
after the nutritional treatment. Accordingly, the lipid profiles were transformed as
 ,
where xij(t)  is  the  concentration of  lipid i in person j at  the  end of  the  treatment  (t=t2) or
prior to the treatment (t=t1). Log-transform modulates the heteroschedasticity of the data
(352).
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As the total number of samples was insufficient for the independent validation, a no hold-
out dataset was utilized for cross-validation. Random subsets cross-validation and Q2
scores were used to optimize the model. Top loadings for latent variables were reported.
The variable importance in the projection (VIP) values (353) were calculated to identify the
most important molecular species for the clustering of specific groups. Multivariate
analyses were performed using Matlab version 7.2 (Mathworks, Inc.) and the PLS Toolbox
version 4.2 Matlab package (Eigenvector Research, Inc.).
Pathway analysis of the gene expression data was performed using Gene Set Enrichment
Analysis (GSEA) method (354) accessed via the gsea-2.0.1 java-application. Expert-curated
gene sets from Molecular Signatures Database (MSigDB, C2 collection) were taken for the
analysis. C2 collection contains gene sets compiled by domain experts from online
pathway databases such as GenMAPP, BioCarta, KEGG, Gene Ontology, Signal
Transduction Knowledge Environment (STKE), and from gene expression signatures of
genetic and chemical perturbations compiled from publications or knowledge of the
expert-curators (354). Pre-ranked gene list analysis was done using 1000 permutations and
gene sets with less than 15 or more than 500 genes were excluded from the analysis. Genes
were ranked as follows. Paired t-test was used to compare gene expressions inside the
groups at baseline and after the intervention and Student’s t-test (unpaired) was used to
compare gene expressions after the intervention between the groups. Genes with P-value
>0.05 were removed and remaining genes were sorted by fold changes. R software version
2.4.1 (355) and simpleaffy package (356) of the Bioconductor project (357) were used for
preprocessing of microarray data and for pre-ranking of genes.
Clinically relevant pathways were selected from the significantly enriched pathways (i.e.,
GSEA results) for further analysis as follows. First, leading edge subsets of the selected
pathways were identified. The leading edge subset of a gene set is defined as the set of its
members that contribute to the peak enrichment score (ES). For a positive ES, the leading
edge subset is the set of members that appear in the ranked list prior to the peak score. For
a negative ES, it is the set of members that appear subsequent to the peak score (354).
Second, gene expression values of the leading edge members of each pathway were
obtained and autoscaled (i.e.,  adjusted to a mean of zero and standard deviation of one).
Third, for the gene pathway profiles we used a PC1-summary, i.e., the first principal
component (353) was extracted from the leading edge genes of each pathway. The
rationale for using the PC1-summary is that it provides the best rank-one decomposition
of the original gene subset data-matrix. In order to capture the change in pathway profiles
we studied the differences yij = yij(t2) – yij(t1), where yij(t) is the PC1-summary of pathway i
in person j prior (t=t1) or after the treatment (t=t2).
Associations between the gene expression pathways and the lipid profiles were studied
using the elastic net regression (358). Elastic net is a flexible regression method that is well
suited for L>>N problems, i.e., problems in which the number of variables (lipids) L is
much larger than the number of samples N. Elastic net regularizes the usual least squares
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parameter estimates by restricting the L1 and L2 norms of the regression coefficients.  As
an implication of this restriction the method simultaneously does automatic variable
selection and continuous shrinkage, and it can select groups of correlated variables. The
number of variables and the degree of shrinkage are tuned with two parameters, one of
which relates to the model size and the other to the extent of L2 penalty on the regression
coefficients. Each pair of tuning parameters corresponds to one elastic net model. The data
were log-transformed as in multivariate analysis described above. Using the differences zij
and yij we built elastic net regression models of type yi = Az + , i.e., models that explain
changes in pathway i with changes in the lipid-profiles. For each pathway, we selected the
regression model that corresponded to the minimum of cross-validated prediction error
curves.
The cross-validation was performed by randomly splitting the 20 subjects into a training
set of size 16 and a test set of size 4. The splitting was randomly performed 100 times, and
each time a regression model was build with the samples in the training data, and that
model was then used to predict the values in the test set. The squared differences between
predictions  and  real  measurements  were  summed  and  averaged  over  all  the  random
splits. In constructing different elastic net models a relatively sparse grid of values for the
parameter that penalizes the L2-norm of the regression coefficients and a more fine-
grained grid for the parameter that relates to the model size were used.  The model that
corresponded to the minimum cross-validation error was selected for further testing. In
this second stage of testing only lipids that were most frequently selected to the minimum
error model were considered, and cross-validated predictions were calculated and
compared with the actual measurements.
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5 Results
5.1 CLINICAL CHARACTERISTICS OF THE STUDY SUBJECTS
In the Fungenut study, the IGI was significantly higher in the OWP group than in the RP
group.  Otherwise,  the  basic  clinical  characteristics  of  the  subjects  did  not  differ
significantly within the studies between the groups.
In the Fungenut study, thy main clinical characteristics did not change significantly during
the  intervention  in  either  the  RP  or  the  OWP  group.  In  the  Fish  study,  systolic  and
diastolic blood pressures decreased (from 123 ± 10 / 82 ± 8 mmHg to 118 ± 11 / 78 ± 7
mmHg, p=0.004 and p=0.001, respectively) in the Lean fish group and increased in the
Fatty fish group (from 122 ± 12 / 80 ± 5 mmHg to 127 ± 9 / 82 ± 4 mmHg, p=0.022 and
p=0.047, respectively). In the control group, there were decreases in serum total cholesterol
(from 4.7 ± 0.8 mmol/l to 4.3 ± 0.8 mmol/l, p=0.027) and HDL cholesterol (from 1.4 ± 0.5 to
1.3 ± 0.4 mmol/l, p=0.028). In the Bread 2 study, body weight decreased (from 69.2 ± 0.8 kg
to 68.8 ± 8.0 kg, p=0.013) and total cholesterol increased (from 6.5 ± 0.7 mmol/l to 6.7 ± 0.8
mmol/l,  p=0.022)  during  the  rye  bread  period,  but  HDL  and  LDL  cholesterol  and
triglyceride concentrations did not change. In the Sysdimet study, the changes in clinical
characteristics did not differ significantly during the intervention among three groups, but
in  within  group  comparisons  the  systolic  and  diastolic  blood  pressures  decreased  in  the
HealthyDiet group (from 137 ± 13 / 89 ± 7 mmHg to 132 ± 13 / 86 ± 7 mmHg, p=0.002 and
p=0.002, respectively).
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5.2 COMPLIANCE OF THE STUDY DIETS AND DIETARY INTAKE
In the Fungenut, Bread 2 and Sysdimet studies the average test bread consumption was ~
8 portions in all groups, except in the control group of the Sysdimet study the average
consumption was around 7 portions. In the Fungenut study, potatoes were consumed 4.5
times and pasta 0.7 times a week in the OWP group. The respective values for the RP
group were 2.5 times and 3.2 times a week. In the Fish study, average fish consumption
during the study was 4.3, 4.7 and 0.6 fish meals per week in the fatty fish, lean fish and
control  groups,  respectively.  In  the  Sysdimet  study,  the  average fish  consumption in  the
HealthyDiet group was 3.3 fish meals per week and average bilberry consumption was 3.2
portions per day.
Daily dietary intakes at baseline and during the intervention periods are presented in
Table 7. In the Fungenut study, dietary intake of protein changed significantly differently
during the intervention periods (p=0.007). Within the OWP group protein intake increased
from 18 E% to 20 E%, whereas in the RP group it lightly decreased.
In  the  Fish study,  the  dietary intake of  total  PUFA,  EPA and DHA increased within the
fatty fish group. Within the lean fish group, the intakes of total energy, total fat, SAFA and
MUFA decreased, and the intake of protein increased. Within the control group, the intake
of EPA decreased during the intervention
In the Bread 2 study, the intake of carbohydrates was higher and total fat,  SAFA, MUFA
and PUFA lower during the intervention periods than during the run-in period, but there
were no differences between the intervention periods. The total fibre intake during the rye
bread period (47 g/day) was considerably higher than during the run-in period (23 g/day)
or the wheat bread period (15 g/day)
In  the  Sysdimet  study,  the  intake  of  EPA,  DHA,  ALA  and  fiber  increased  in  the
HealthyDiet group compared with the changes in the control group. Total intake of PUFA
decreased  significantly  less  in  the  HealthyDiet  group  than  in  the  control  group,  but  the
decrease within the HealthyDiet group was not significant. The decrease of SAFA was
significant within the HealthyDiet group and nearly significant when comparing with the
changes  in  the  control  group.  In  the  WGED  group,  the  intake  of  total  fat  decreased  and
fiber increased compared with the control group.
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5.3 FATTY ACIDS
Dietary carbohydrate modification did not change serum/plasma FA content markedly
(Fungenut  study and the  WGED group of  the  Sysdimet  study).  The only  change in  fatty
acid content that occurred after the carbohydrate modification interventions, was the
increase in the content of serum DHA in the RP group (p=0.01) in the Fungenut study. In
the Sysdimet study, there were no significant changes in plasma fatty acid content in the
WGED group.
In the Fish study, proportions of plasma oleic acid and di-homo--linolenic acid decreased
and those of ALA, arachidonic acid, EPA, docosapentaenoic acid (DPA) and DHA
increased  within  the  Fatty  fish  group.  In  the  Sysdimet  study,  the  changes  were  very
similar  in  the  HealthyDiet  group,  in  which  the  proportions  of  di-homo--linolenic  acid
decreased and EPA,  DPA and DHA increased compared with the  control  group.  Within
the HealthyDiet group also increases of stearic acid and ALA, and decreases of oleic acid,
cis-vaccenic acid and arachidonic acid were significant.  In the lean fish group of the Fish
study, only the proportion of cis-vaccenic acid increased. No significant changes in plasma
fatty acids were observed in the control group of the Fish study. In the control group of
the Sysdimet study, the proportions of DHA decreased during the intervention. Effects of
fish intake on the most relevant plasma fatty acids are presented in the Table 8.
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5.4 LIPIDOMICS
A total of 278, 320, 309 and 364 lipids (Studies I-IV, respectively) were identified and
quantified by the UPLC-MS lipidomics platform including lipid classes such as TGs, LPCs,
PCs,  PSs,  PEs,  SMs  and  ceramides.  We  established  that  there  were  no  significant
differences in lipids between the groups within the studies at baseline.
5.4.1 Effects of grain products on serum or plasma lipidomics
Effects  of  grain  products  on  serum  or  plasma  lipidomic  profiles  were  studied  in  the
Fungenut,  Bread  2  and  Sysdimet  (WGED  group)  studies.   In  the  Fungenut  study,  there
were  no  significant  changes  in  lipidomic  profiles  after  the  low  insulin  response  RP  diet.
The major difference following the diet with high insulin response (OWP) in the Fungenut
study  was  the  increase  of  multiple  LPC  species  (Figure  7).  In  the  Sysdimet  study,  when
comparing within-person changes in the WGED group, there were altogether 91 lipids
that significantly changed(FDR p < 0.05) after the 12-week consumption of whole grain
and low insulin response grain products, but when comparing changes to the changes in
the control group, there were no significant differences.
In the Bread 2 study, we studied the effect of high-fiber rye bread or white-wheat bread on
plasma  lipidomic  profiles,  but  we  did  not  find  any  significant  changes  during  the  diets.
However, SM(d18:1/25:1) and SM(d18:1/25:3) were higher (q=0,016 and q=0.016) at the end
of the rye bread period than at the end of the wheat bread period.
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Figure 7. Averages of  fold changes for  multiple LPC species,  with 95% confidence interval  in
the OWP and RP groups. The RP group is represented with gray bars and the OWP group with
white bars. Multiple LPC species were significantly increased in the OWP group, whereas there
were no changes in the RP group. * P<0.05 within a group (paired Wilcoxon signed rank test).
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5.4.2 Effects of fish on plasma lipidomics
The change in 240 lipids differed across the three groups of the Fish study during the
intervention.  When  comparing  within-person  changes  across  the  three  groups,  no  lipids
were significantly altered in the control group, while 63 and 5 lipids changed in the fatty
and lean fish groups, respectively. Multiple bioactive lipid species, including ceramides,
LPCs, DGs, PCs and lysophosphatidylethanolamines, decreased significantly in the Fatty
fish group, whereas in the lean fish group cholesterol esters increased significantly (Figure
8). We also studied the relation between lipidomics variables and the sum of EPA and
DHA using mixed models. We found that plasma content of EPA and DHA strongly
associated with the plasma long chain TGs, ChoE(20:5), LPC(20:5), specific
phosphatidylcholines and ether bonded phosphatidylethanolamines (plasmalogens).
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Figure  8.  Bar  charts  of  fold  changes  for  different  lipid  classes  (calculated  as  a  sum  of  lipid
concentrations within class) in each group (Study II).  *, P<0.05; **, P<0.01; ***, P<0.001.
P-values were calculated using paired samples t-test within a group.
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5.4.3 Combined effects of grain products, fatty fish and bilberries on plasma lipidomics
The combined effects  of  whole  grain  and low insulin  response grain  products,  fatty  fish
and bilberries on plasma lipidomic profile were assessed in the Sysdimet study. In within-
group-comparisons, 152 lipids changed in the HealthyDiet group. When comparing
changes between the HealthyDiet and control groups, there were 25 lipids that
significantly changed in the HealthyDiet group (Table 9). These changes include increases
of multiple TGs containin long-chain PUFAs, LPC(20:5), PC(36:5), PC(38:7e), PC(40:7e) and
TG(55:7), and decreases in  PS(38:2) and LPC(20:3). LPC(22:6) increased within the
HealthyDiet group (FDR p=0.005), but in a comparison of all three groups together this
increase did not reach the level of statistical significance (FDR p=0.088). Odd chain TGs,
except for increased TG(55:7), and ceramides did not change during the intervention.
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Table 9. Lipids, which changed significantly during the 12-week consumption of whole grain
and low insulin response grain products, fatty fish and bilberries in the Sysdimet study
HealthyDiet
compared with the
control group
With-in-group
comparison
(HealthyDiet)
Lipids Beta FDR p1 Beta FDR p2
TG(60:12) 0.458 3x10
-4 0.418 3x10
-6
TG(60:12)3 0.433 5x10
-4 0.413 5x10
-6
TG(60:13) 0.349 0.007 0.351 7x10
-6
LPC(20:5) 0.212 0.007 0.152 0.002
TG(58:11) 0.328 0.008 0.370 4x10
-6
TG(56:10) 0.244 0.013 0.305 4x10
-6
TG(58:11)3 0.285 0.013 0.339 4x10
-6
PC(36:5) 0.192 0.013 0.235 4x10
-6
PS(38:2) -0.135 0.013 -0.087 0.010
PE(38:4)/PC(35:4) -0.130 0.013 -0.022 0.434
PC(38:7e) 0.131 0.013 0.114 2x10
-4
PE(38:7e)3 0.198 0.013 0.199 2x10
-5
PC(38:4e) -0.136 0.013 -0.033 0.334
PC(40:7e) 0.140 0.013 0.111 3x10
-4
TG(56:6) 0.171 0.019 0.179 6x10
-6
TG(54:8) 0.252 0.020 0.310 5x10
-6
TG(58:10) 0.237 0.026 0.301 4x10
-6
TG(55:7) 0.272 0.036 0.291 7x10
-5
LPC(20:3) -0.123 0.040 -0.063 0.041
PE(40:7) -0.130 0.040 -0.076 0.032
PC(40:4) -0.228 0.040 -0.040 0.583
PC(38:7) 0.152 0.040 0.187 1x10
-5
TG(58:10)3 0.218 0.041 0.305 4x10
-6
TG(56:9) 0.217 0.041 0.314 4x10
-6
PC(40:7e) -0.147 0.041 -0.030 0.476
1Mixed model analysis, Interaction of time and group (time*group), the HealthyDiet group compared to
the controls, age, gender, BMI, insulin and glucose used as covariates 2Effect of time within the
HealthyDiet group, age, gender, BMI, insulin and glucose used as covariates 3Lipids which are mentioned
twice are isobaric, i.e. that the fatty acid composition differs
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5.5 METABOLOMICS
5.5.1 Branched chain amino acids
In the Fungenut study we evaluated the effects of low and high insulin response grain
products on the serum branched chain amino acids (BCAA), valine, leucine and isoleucine
(Figure 9). We found that isoleucine decreased in the RP group. There were no significant
changes in other BCAA.
Figure 9. Serum isoleucine content before and after the intervention in the rye bread and pasta
(RP) and in the oat and wheat bread and potato (OWP) groups in the Fungenut study. Values
are means ± SEM. P-value was calculated using paired samples t-test.
5.5.2 GCxGC TOF metabolomics
In  the  Bread  2  study,  altogether  231  metabolites,  including  organic  acids,  sterols  and
alcohols, were identified by the GCxGC-TOF-MS. Of those metabolites Ribitol and ribonic
acid  (RA)  increased  during  the  rye  bread  period  (Figure  10).  There  was  also  a  trend  for
increased indoleacetic acid (IAA) during the rye bread period. Those changes were
significantly different compared with changes during the wheat bread period. RA
concentration correlated positively with tryptophan concentrations before the rye bread
period (r=0.38, p=0.03), and their concentration changes during the RP period were also
correlated (r=0.40, p=0.03). The association remained significant after adjusting with
changes in body weight (r=0.37, p=0.05).
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Figure 10. Peak  areas  of  plasma  ribitol,  ribonic  acid  (RA)  and  indoleacetic  acid  (IAA)  in
postmenopausal women after consuming wheat bread (WB) and rye bread (RB) for 8 weeks.
Values  are  means  ±  SEM  , n= 35  (WB)  or  29  (RB). q-values were calculated from p-value
distribution obtained from paired samples t-test.
5.6 ADIPOSE TISSUE PATHWAYS AND SERUM LIPIDOME
In  the  Fungenut  study,  several  gene  sets  related  to  stress  reactions,  adipose  tissue
differentiation and DNA damage signaling were up-regulated in the OWP groups,
whereas pathways related to stress reactions, insulin signaling and energy metabolism
were down-regulated in the RP group. To investigate whether any of these pathway
changes observed in adipose tissue were reflected in the serum lipidome, regression
analysis  of  lipidomics  profiles  on  selected  pathways  found  affected  by  the  carbohydrate
modification was performed. Lipid profiles had the strongest association with the changes
in the adipose tissue differentiation pathway. PC(38:7), PE(36:2), PE(42:5e), TG(54:5),
TG(58:8), ChoE(20:4), ChoE(22:6) and LPC(18:0) were the lipids which were most strongly
and inversely related to expression in the adipose tissue differentiation pathway.
5.7 EFFECTS OF GRAIN PRODUCTS, FISH AND BILBERRIES ON
GLUCOSE AND INSULIN METABOLISM
In the Sysdimet study we studied the effect of whole grain and low insulin response grain
products, fatty fish and bilberries on glucose and insulin metabolism. There were no
significant differences in glucose and insulin metabolism among the three groups. In the
HealthyDiet group, within-group comparison revealed decreases in the two hour glucose
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concentration and AUC (Figure 11). There was also a trend for improved IGI (p=0.016 and
FDR p=0.076) and DI (p=0.019 and FDR p=0.076) within the HealthyDiet group (Figure 11).
In regression model analyses, there were significant associations between the changes in
plasma EPA and DHA with the changes in IGI (p=0.009 and p=0.006) and DI (p=0.009 and
p=0.005, respectively). The inclusion of changes in the fiber intake in the regression model
did not alter the associations.  There were also positive correlations between the changes
in EPA and DHA and changes in IGI (r=0.31, p=0.002 and r=0.41, p<0.001, respectively) and
DI (r=0.31, p=0.002 and r=0.34, p=0.001, respectively). Changes in IGI and DI during the
intervention period according to quartiles of changes in plasma EPA and DHA content are
presented in Figure 12.
Figure 11. Bar charts of A) plasma 2-hour glucose, B) area under the curve (AUC) for glucose,
C) Insulinogenic index and D) Disposition index in oral glucose tolerance test (OGTT) before (0
wk) and after  (12 wk) the dietary intervention in the HealthyDiet, Whole grain enriched diet
(WGED) and control groups in the Sysdimet study. Values are means ± SEM
63
Figure 12. Changes in Insulinogenic index (IGI) (A and B) and Disposition index (DI) (C and D)
during the intervention period (95% confidence interval) according to quartiles of changes in
plasma  EPA  (A  and  C)  and  DHA  (B  and  D)  content  (%).  *p<0.01,  Kruskal-Wallis  test.  All
groups combined (n=99).
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6 Discussion
6.1 METHODOLOGICAL CONSIDERATIONS
6.1.1 Study population
All study subjects were carefully selected and clinically well characterized. In two of the
studies (Fungenut and Sysdimet), subjects had features of the MetS. Subjects in those two
study populations were much alike, characterized by obesity and increased waist
circumference, and elevated blood pressures, moderate dyslipidemia and impaired
glucose metabolism. However, at the individual level there were small differences in these
features. For example, in the Sysdimet study, fasting glucose at baseline ranged from 5.2 -
7.8 mmol/L. This could partly explain different responses to the diet at individual level.
In the Fish study, the subjects were highly medicated CHD patients. They were also older
than participants in the other studies. In the Bread 2 study, subjects were post-menopausal
women with dyslipidemia, but they had normal glucose metabolism. Despite differences
in  clinical  characteristics  among  the  subjects,  all  subjects  had  an  elevated  risk  for  T2DM
and  adverse  CVD  events,  which  makes  them  a  target  group  for  dietary  interventions  to
prevent these diseases. The study population in the Fish study might have been the least
comparable to the other study populations included in this thesis and also to the general
population overall. In the Fish study, all subjects were using multiple medications
including statins, which are known to cause drug-specific changes in the plasma lipidomic
profile (359). Use of medications may have confounded the possible effects of diets in all
studies, but it is not possible to study CHD patients without medications.
Within the studies, clinical characteristics did not differ between the groups at baseline,
except in the Fungenut study the present subgroups differed by gender, and the IGI was
significantly higher in the OWP group. Subjects in the OWP group also tended to be less
obese and have lower serum triacylglycerols than in the RP group. However, this did not
affect within group comparisons of lipidomics.
A limitation of  especially  the  Fungenut  and Fish studies  was the  small  sample  size.  It  is
possible that the power of the studies was insufficient to detect all diet-associated
metabolic changes. Power analyses were conducted before the studies for primary
outcome measurements, which basically were clinically used measurements for glucose or
insulin metabolism. Power analyses would have been difficult to perform for metabolic
profiling studies, because it is not easy to select specific variables for power calculations
and determine clinically relevant changes. The methods that were employed in these
intervention studies were extensive, time-consuming and expensive (e.g. adipose tissue
biopsy) and therefore difficult to apply to much larger study populations. From this point
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of view, the Sysdimet study was a comparatively large dietary intervention with much
better statistical power to detect true changes.
6.1.2 Interventions
In all four studies, self reported compliance with the intervention diets was good.
However, measurement of dietary intake is always a challenge. Dietary records are prone
to bias. Here we used daily records of test foods and food diaries with four consecutive
days including a weekend day, which is probably the most accurate of the self-report
methods (360). Subjects were given the main products free of charge in all studies, which
improves the compliance to the diets. The compliance of the study diets could be
evaluated also based on certain biomarkers measured in some of these studies.
Alcylresorcinol  concentration,  which  is  considered  to  be  a  biomarker  of  whole-grain  rye
and wheat intake, more than tripled during the rye bread period of Bread 2 indicating
good compliance of the study diet (361). In the Fatty fish group of the Fish study, plasma
EPA nearly doubled and DHA was 1.4 times higher at the end of the intervention period,
which could have not occurred without an increased intake of fatty fish or fish oil. In the
HealthyDiet group of the Sysdimet study, the plasma EPA was 1.6 times and DHA 1.2
higher at the end of the study. Overall, the participants found the intervention diets easy
to follow, and adverse symptoms related to the diets were reported very seldom. The
symptoms reported were mainly related to the control diets, which were low in dietary
fiber (including constipation and tiredness).  Good compliance and satisfaction with
consuming the study diets indicated that rye bread, bilberries and fish may offer a
practical dietary means for Finnish subjects to possibly beneficially affect their glucose and
lipid metabolism.
In the Finnish population, and especially in the geographical area of this study and age
group of middle-aged and older subjects, a drastic increase of dietary intake of rye bread is
difficult to obtain, since these people habitually consume a lot of rye bread in their diet.
Therefore, this population may not have been optimal to see effects of rye and low insulin
response grain products, because the change in the diet relative to the habitual diet was
only modest. As seen in the Fungenut study, carbohydrate modification affected the
molecular profiles of the OWP group more than the RP group, since subjects in the OWP
group probably had to change their diet substantially more than subjects in the RP group.
In contrast, the aim to increase fish intake is easy to achieve in the Finnish population,
since  the  average  consumption  of  fish  is  only  24  g/day  in  women  and  28  g/day  in  men
meaning less than two fish meals per week (232). In the Northern-Savo and Northern-
Karelia, the intake of n-3 PUFAs among women is even lower than elsewhere in Finland
(232). Among men in Nothern-Savo it is nearly average. Accordingly, in the interventions
with fish, we saw remarkable changes in lipid profiles.
One of the difficulties in human nutritional studies is that it is impossible to change only
one  thing  in  a  diet.  If  we  aim  to  increase  something  in  a  diet  while  maintaining  body
weight constant, it is necessary at the same time to decrease something else. That was seen
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also in the present studies. For example, in the carbohydrate modification studies the aim
was to replace habitually used grain products with the test products and maintan the diet
otherwise unchanged. However, in both Fungenut and Bread 2 studies, in addition to
increases in carbohydrate intake, also within-group changes in the dietary intake of fat
were seen, which may confound the effects of carbohydrate modification. Thus, the
positive or negative effects related to certain diet may also originate from absence of food
or  nutrients  which  were  replaced  with  the  test  products  rather  than  test  products
themselves.
6.1.3 Analytical methods
Besides routine clinical measurements, also novel metabolomics, lipidomics and
transcriptomics methods were utilized in this thesis. The lipidomics platform used in these
studies affords broad screening of multiple lipid classes in a single sample run, and it has
been applied in several clinical studies so far (178, 179, 359). As a relatively new
methodology there are still challenges to overcome, of which probably the most important
is the correct identification of the lipids. Fortunately, identification of more and more
lipids has been confirmed with MS/MS analyses.
The body fluid investigated in our studies was serum or plasma. Of all body fluids, serum
and plasma are the most commonly used and it reflects endogenous processes, including
inter-organ communication, energy metabolism, inflammation and disease state. In
contrast, urine, which is also often used in metabolomics studies, generally reveals
exposure and environmental challenges (14). Urine has been shown to reflect acute dietary
intake more sensitively than plasma (26).  The lipid composition of serum is more closely
related to that of the liver than to adipose tissue (362).
The use of internal standards for quantification of metabolites needs to be considered
carefully in a perspective of clinical relevance in nutritional studies. FA 17:0 is a very
commonly used standard in fatty acid analyses and unfortunately it was used also in our
studies. However, FA 17:0 has also been considered as a biomarker of dairy fat intake, in
spite of the rather questionable evidence of its reliability as indicator of dairy fat intake
(363-365). If we would have measured the plasma content of 17:0, there would have been a
good possibility to estimate the reliability of the FA 17:0 as biomarker of dairy fat in a
context of controlled dietary interventions with well documented dietary intake.
In the Fungenut study, microarray data was analyzed using GSEA and clinically relevant
pathways were selected from the significantly enriched pathways for further analysis.
Single gene analyses may miss the important enrichment of set of genes in the same
pathway, so the GSEA was developed to overcome this analytical challenge (354). The
results from GSEA were consistent with earlier analyses done with the same data, but
complemented the previous analyses with the finding of up-regulation of genes related to
adipose tissue differentiation in the OWP group (240).
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6.1.4 Statistical issues
It could be argued whether the statistical methods used in the studies are the most
appropriate. Different methods have been used to estimate significant changes during the
intervention, which may complicate the comparison of the results between the studies.
Especially in the first study, we focused on within-the-group changes since the huge inter-
individual variability of metabolite concentrations hampers detection of changes in
between group comparisons. However, within group comparisons also measure the effect
of  time,  and  thus  comparing  changes  between  the  intervention  and  control  groups
provides the most reliable information on the effects of a diet, as we did using mixed
model analyses in the Sysdimet study. Adjustment for possible confounding factors is also
an issue of debate. In the Sysdimet study, we included age, gender, BMI, insulin and
glucose in the models as covariates, but this was not done in the first three studies.
To  correct  for  multiple  comparisons,  FDR q-values (348) or Benjamini-Hochberg FDR p-
values (366) were calculated in metabolomics analyses.  The reason to report FDR p-values
instead of q-values in the Sysdimet study, was that q-values did not work properly in a
situation where the p-value  distribution  mainly  consisted  of  very  small  values.  In  the
Sysdimet study, all p-values, including also clinical and dietary parameters, were
corrected for multiples testing by FDR p-values. With uncorrected p-values, type I errors
(false  positive)  may  occur,  but  on  the  other  hand  correction  for  multiple  testing  may
introduce type II errors (false negative results). However, FDR approaches are less
conservative than e.g. traditional Bonferroni correction, and have greater ability to find
true positive results.
6.2 RESULTS
6.2.1 Effects of grain products
In Studies I, III and IV we saw that low insulin response grain products, whole grain and
rye caused rather minor changes in plasma lipidomic profile. While the dietary
modification in  the  Fungenut  and Sysdimet  (WGED group)  studies  was relatively  small,
postmenopausal women in the Bread 2 study drastically increased their dietary fiber
intake and due to crossover design it was also possible to compare the effects of wheat
bread diet and rye bread diet in the same participants. However, changes in the lipidomic
profile  were  not  found  in  the  Bread  2  study.   Dietary  fiber  of  rye  consists  mostly  of
insoluble fiber which does not seem to affect lipid metabolism, whereas soluble fiber
effectively decreases LDL cholesterol (367). However, Leinonen and colleagues showed
that 4 weeks of consumption of rye bread as a part of the usual diet decreased serum total
cholesterol  in  men with elevated serum cholesterol  by 8  % on average,  but  did not  alter
cholesterol in women (241).  In the future, the effects of diet modification on lipidomic
profiles would be interesting to examine also in separate sex groups.
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In the Fungenut study, we demonstrated that 12 weeks of consumption of high insulin
response OWP diet altered serum lipidomic profile by increasing LPC lipids. As LPCs are
known to be the main components of oxidized LDL (155), the increased LPC content may
indicate increased lipid peroxidation during the OWP diet, whereas the RP diet had not
the  same  effect.  This  may  be  explained  by  higher  content  of  fenolic  compounds  and
antioxidants in traditionally baked rye breads than in wheat rolls (368). In addition, it has
been shown that intake of whole grain foods, in combination with other plant products,
decrease markers of lipid peroxidation (369). When considering LPCs it is important to
note, that their biological function may vary depending on the acyl chain. In this case,
increased species were bound with saturated or n-6 fatty acids (Figure 7). LPCs increase
inflammatory cytokines in human peripheral mononuclear cells (163) and human
monocytes (164) and the effect is stronger with saturated LPCs compared with
monounsaturated ones. The increase of LPCs during the OWP diet is consistent with the
findings by Kallio and colleagues (370), suggesting that the OWP diet increased adipose
tissue gene expression and serum concentration of proinflammatory cytokines.
Besides lipidomics, we also studied the effects of grain products on other metabolites. In
the  Fungenut  Study,  we  found  decrease  in  the  BCAA  isoleucine  after  the  RP  diet.  High
serum BCAA concentrations have been associated with decreased BCAA catabolism,
obesity and hyperinsulinemia, which suggest that decrease of BCAA may be associated
with better insulin sensitivity after the RP diet (371). However, this result needs to be
considered with reservation, since the dietary intake of protein decreased during the RP
period making it likely that also dietary intake of isoleucine decreased, which could also
explain as decreased serum isoleucine concentrations. Isoleucine is one of the essential
amino acids which can not be synthesized de novo by humans, and therefore must be
supplied in the diet.
In the Bread 2 study we found that the 8-week consumption of high fiber rye bread led to
increased  levels  of  ribitol,  RA,  and  IAA.  Ribitol  and  RA  are  precursors  and  IAA  is  a
breakdown product of tryptophan. There is some preliminary evidence that serum
tryptophan concentration is low in obese people and it does not change after weight loss
(372). Tryptophan is a precursor for the biosynthesis of serotonin which inhibits
neuropeptide Y expression, thus depressing hunger. Serum tryptophan concentrations
have  been  found  to  be  stable.  Accordingly,  we  did  not  detect  any  changes  in  plasma
tryptophan concentrations within or between the different diets. However, it could be
hypothesized that the increases of its precursors ribitol and RA, and its break-down
product IAA after the rye bread diet may mediate positive effects of higher tryptophan
concentration, resulting in decreased appetite and food intake. There was a small decrease
in  body  weight  during  the  rye  bread  period,  despite  the  advice  to  keep  body  weight
unchanged throughout the study, which also supports this hypothesis. Furthermore, in
post-prandial studies the intake of rye is linked to higher subjective satiety after the meal
(235, 237, 237).
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In the Fungenut study, we also examined effects of grain products at the level of adipose
tissue gene expression. We found that gene sets related to stress reaction, adipose tissue
differentiation, and DNA damage signaling were up-regulated in the OWP group,
whereas pathways related to stress reaction, insulin signaling and energy metabolism
were  down-regulated  in  the  RP  group.  In  exploratory  analyses  we  also  examined
dependencies between the observed lipidomic profile changes and specific gene
expression pathways. We found that the changes in lipid profiles associated strongest to
the adipose tissue differentiation pathway. Key lipids in this association included e.g.
decreased cholesterol esters, which may be related to their accumulation in the adipose
tissue during the differentiation of adipocytes (373).
6.2.2 Effects of fish
The effect of fatty fish and lean fish intake was studied in Study III. We found that the 8-
week consumption of fatty fish altered the lipidomic profile markedly, while the lean fish
or control diet did not cause such changes. The plasma lipids found affected by the fatty
fish diet, are associated with insulin signaling and inflammation. Diminished lipid species
included ceramides, DGs and LPCs.  DG and ceramides are potential mediators of lipid-
induced insulin resistance as discussed in the Review of the literature chapter. LPCs,
which were found to be increased after the OWP diet, decreased after the fatty fish diet.
Hypothetically, a high intake of fatty fish may diminish some of the negative effects of a
high insulin response diet, which may give more alternatives for building up a healthy
diet. However, this hypothesis is probably oversimplified and would need to be confirmed
by clinical trial before it could be converted to clinical benefits.
Even  though  the  aim  of  the  Sysdimet  study  was  to  study  combined  effects  of  grain
products, fish, and bilberries, we could separate some effects related to fish intake. We
found that the increase in plasma EPA and DHA content was associated with improved
glucose metabolism as assessed by increased IGI and DI. Decreased AUC for glucose and
a trend towards improved IGI and DI in the HealthyDiet group, but not in the WGED
group  also  suggest  that  especially  the  intake  of  fatty  fish  had  positive  effects  on  insulin
secretion and glucose  disposal  in  this  study.  These  effects  could also  be  synergistic  with
grain products and bilberries. Associations between the changes in plasma EPA and DHA
content  and  improved  IGI  and  DI  were  curvilinear,  meaning  that  the  improved  insulin
secretion and glucose disposal existed only in the highest quartiles of changes in EPA and
DHA. We did not find changes in the insulin sensitivity or lipids, e.g. ceramides, linked to
insulin resistance.
The relationship between insulin sensitivity and insulin resistance is hyperbolic, such that
as insulin sensitivity decreases, normal -cells increase their insulin response to maintain
normoglycemia. T2DM occurs when reduced insulin sensitivity cannot be compensated
for increased insulin secretion (374). -cell dysfunction is commonly characterized by the
loss of first-phase insulin secretion and is a prerequisite for the development of impaired
glucose tolerance. The possibility to affect first-phase insulin secretion by diet is key,
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because it seems to be primary determinant of which persons with insulin resistance who
eventually  develop  IGT  or  T2DM  (375).  The  DI,  which  is  the  product  of  measures  of
insulin sensitivity and first-phase insulin secretion, has also been shown to predict
conversion to diabetes (376, 377).
Genome-wide association studies have identified more genetic variants that enhance risk
of type 2 diabetes affecting beta cell function causing impaired insulin secretion than
genes contributing to insulin resistance (378). However, high insulin sensitivity could
protect against the detrimental effects of several genes on insulin secretion (379). These
compensatory mechanisms might be effective in the non-diabetic range of glycaemia, but
are likely to fail when frank hyperglycemia develops (378).
In the Fish study, plasma EPA and DHA contents were associated with the LPC(20:5). In
the Sysdimet study we found increase in LPC(20:5). LPC(22:6) also increased within the
HealthyDiet group, but among the groups the change did not reach the level of statistical
significance. Block and colleagues (167) demonstrated that dietary EPA and DHA fatty
acids are incorporated into plasma LPCs. The ability to increase LPC(20:5) and LPC(22:6)
with dietary ingestion of fatty fish may be important, since LPC are believed to be major
carriers of DHA to the brain (168).
Partly by trial and error,  we paid attention to increased and stable odd chain TGs in the
Sysdimet  study.   Those  TGs  with  the  odd  number  of  carbons  most  likely  include  15:0
and17:0 fatty acids, which have been considered to be biomarkers of dairy fat intake, and
thus have even hypothesized to have protective effects against heart disease, stroke and
insulin resistance (380-383). However, the association between the intake of dairy fat and
relative serum content of 17:0 have not been clear in every study (384) and also inverse
associations have been observed (365). Furthermore, in the large EPIC cohort, there was a
strong positive correlation (r=0.8, p0.01) between the total intake of fish and plasma
content of 17:0 (385).
In the Sysdimet study, dietary intake of SAFA decreased from 12 E% to 10.7 E% within the
HealthyDiet group. This indicates compliance to the instruction to avoid cream and butter
in fish preparation. Therefore, the decreased dairy fat intake should also have been
reflected as a decrease in serum odd chain fatty acids, if these could be considered as good
biomarkers for dairy fat intake.  Fatty acid 17:0 is present in the fat of fish in low amounts
(0.31-2.0% depending on fish species) (386, 387). Our results suggest that intake of odd
chain fatty acids from dairy fat decreased, but a corresponding amount came from
increased fatty fish intake, keeping the plasma concentration constant. Therefore, it may be
questionable  to  consider  odd chain fatty  acids  as  biomarkers  of  dairy  fat  intake,  and the
associated health effects might be related to high intake of fish rather than dairy products.
This issue definitely needs to be confirmed with a controlled clinical trial.
Many controlled experimental studies have focused on the effects of supplemental n-3
long-chain PUFAs rather than the effects of fish consumption. The effect of fish was
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studied in the present study and it is impossible to know if these effects would have been
obtained also with fish oil supplements. In the Fish study, lean fish did not have the same
effect as fatty fish. However, it is still possible that fatty fish contains components other
than fish  oil  which may have effects  on health.  It  would have been interesting to  have a
parallel group with fish oil supplements containing the same amount of EPA and DHA as
obtained from fish in the fatty fish group.
6.2.3 Combined effects of grain products, fish and bilberries
The combined effect of whole grain and low insulin response grain products, fatty fish and
bilberries were studied in the Sysdimet study. We found 25 lipids that significantly
changed in the HealthyDiet group when comparing changes among the groups. Improved
glucose metabolism was also found within the HealthyDiet group. As discussed above,
those changes seemed to be related mostly to increased fish intake. However, we cannot
exclude  the  possibility  of  the  synergistic  effects  of  fish,  grain  products  and  berries.  For
example, bilberries may have had a role in the improved glucose metabolism. Stull and
colleagues recently (345) showed that insulin sensitivity was enhanced after a 6 wk dietary
supplementation with bioactive substances from bilberries in 32 obese, insulin-resistant
subjects.
6.2.4 Metabolomics in dietary interventions
These four applications of metabolomics and lipidomics in the dietary intervention studies
showed that this growing, but still uncommonly used method in nutrition science is a
feasible tool for studying the effects of diet. Metabolomics and other omics approaches
allow characterization of the effects of a nutrient, a food or a diet in a much broader
contect than classical approaches in nutrition research (14). When trying to understand
genes and environment interactions, different omics approaches complement each others.
Stress conditions that challenge the homeostasis of a biological system can result in
pronounced compensatory response at the transcript and protein levels but relatively
minor changes in metabolism (388).  On the other hand, small mutation in the genome, e.g.
single amino acid change, can result relatively small changes in the transcriptome and
proteome but more pronounced changes in the metabolome when resulting partial or
complete  loss  of  enzymatic  function.  In  the  Fungenut  study,  we studied the  effect  of  the
diet both at transcriptomic and metabolomic levels and found rather minor changes at the
level  of  metabolism  even  though  there  were  many  alterations  in  the  adipose  tissue
transcriptomics. However, only small piece of metabolome was studied, in particular lipid
metabolism, so it is impossible to draw conclusions about other changes in the
metabolome overall.
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6.3 SUMMARY AND FUTURE PERSPECTIVES
The growing prevalence of T2DM and the fact that CVD is still the leading cause of death
reinforce  the  need  to  discover  dietary  solutions  that  may  improve  glucose  and  lipid
metabolism and prevent these diseases in high-risk subjects (389, 390). MetS, a cluster of
major cardiovascular risk factors related to overweight and insulin resistance, causes a 5-
fold increase in risk for T2DM and more than doubles the risk for CVD (63-67). In studies
included in this thesis, we aimed to elucidate the possible effects of specific grain
products,  fish  and  bilberries  on  lipid  and  glucose  metabolism  in  subjects  with  increased
risk for T2DM or CVD using metabolomics and lipidomics approaches. These novel
methods gave new information about the possible mechanisms by which these dietary
components may affect human health.
We observed that diet rich in whole grain, rye, or other low insulin response grain
products did not change the lipidomic profile markedly. Instead, when customarily used
grain products were replaced with high insulin response grain products, including wheat,
oat and potatoes, proinflammatory LPC lipids increased, which may in turn promote
adverse changes in insulin and glucose metabolism in the long run. On the other hand,
high fiber rye bread may help maintain or decrease body weight by increasing metabolites
related  to  satiety,  which  in  turn  decreases  the  risk  for  obesity,  MetS  and  consequent
diseases. It remains to be clarified whether a weight loss diet combined with high intake of
rye  bread  induce  higher  weight  loss  than  weight  loss  diet  including  different  grain
products.
The epidemiological evidence of the beneficial effects of consumption of fish and n-3 fatty
acids on prevention of CVD progression, events and mortality is consistent, and the trial
evidence suggestive. Epidemiological studies have also demonstrated associations
between fish and n-3 fatty acids and lower prevalence of insulin resistance and T2DM, but
this association has not been seen in all studies. These associations were supported by
findings in Studies II and IV, which demonstrated remarkable effects of fatty fish
consumption on lipid metabolism. Interestingly, lipids affected by consumption of fatty
fish  were  associated  with  insulin  signaling  and  inflammation.  Furthermore,  in Study IV,
increases in the plasma EPA and DHA contents were associated with improved insulin
secretion and glucose disposal. This may be a clinically relevant finding, because impaired
first  phase  insulin  secretion  seems  to  be  primary  determinant  of  which  persons  with
insulin  resistance  who eventually  develop IGT or  T2DM, and the  majority  of  genes  thus
far found to be related to an increased risk of T2DM affect insulin secretion (375, 391).
Weight loss and exercise are effective ways to improve insulin sensitivity and decrease the
risk of T2DM (392). However, in subjects with severe obesity these may be sometimes
difficult to achieve. Therefore, an increase of fish intake, whole grain products and
bilberries may be easier firs-step towards a healthier lifestyle and better glucose
metabolism.
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This thesis indicated that metabolomics is a valuable tool in nutrition science that helps
elucidate the complex relationship between nutrition and metabolism and role that dietary
components play in health maintenance and disease development. Furthermore, it may
serve as a tool for dietary intake monitoring, if reliable biomarkers for food consumption
are found. However, thus far it is possible to assess only a small piece of the entity of
metabolism. In these studies we focused on lipid metabolism. Analytical technologies and
information technology advance contuously, and knowledge on human metabolites
increase. In the end, the most demanding task is the translation from metabolite
concentration changes in body fluids to organ biochemistry and whole-body physiological
interpretation and further into useful guidelines for prevention and treatment of diseases.
In future studies, comprehensive understanding of dietary effects needs systems biology
approaches, including transcriptomics, proteomics and metabolimics, combined with the
appropriate experimental design with carefully controlled diets and adequate size of the
study  population  to  be  able  to  find  true  changes  related  to  a  diet.  Such  studies  will
necessitate networking and team work among multi-professional study groups.
6.4 CONCLUSIONS
Taken together, this thesis indicated that even relatively small changes in diet altered
metabolic profiles, especially lipids related to peroxidation, inflammation and insulin
signaling.  This  complements  earlier  evidence  that  a  diet  rich  in  fatty  fish,  bilberries  and
whole grain and low insulin response grain products including rye, may have a beneficial
role  in  the  prevention  of  T2DM  and  CVD  in  high-risk  individuals.  These  foods  have
traditionally been part of the Finnish cuisine, but during the last few decades have been
partly replaced by white wheat, red meat and snacks high in sugar and saturated fat.
Especially among adolescents and young adults, the increased intake of foods such as
whole grain rye, fatty fish and bilberries would be important, not only with respect to
economic  and  environmental  concerns,  but  also  for  health  reasons.  Furthermore,  this
thesis showed that metabolomics is a valuable tool for studying the effects of diet at the
molecular level.
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This study focused on the effects of 
grain products and fish on metabolic 
profile. Metabolomics and lipidomics 
are modern technologies that allow 
characterization of the effects of diet 
in a much broader context than more 
conventional approaches in nutrition 
research and could therefore help 
elucidate the complex relationship 
between nutrition and metabolism. 
This thesis indicated that even rela-
tively small changes in diet altered 
metabolic profiles, especially lipids 
related to peroxidation, inflamma-
tion and insulin signaling.
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